var title_f34_26_35232="Pelvic inlet view xray";
var content_f34_26_35232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Inlet view for radiograph of pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The inlet view of the pelvis is performed with the x-ray beam oriented 40 degrees cephalad.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gibbs, MA, Bosse, MJ. Pelvic Ring Fractures. In: Trauma Management: An Emergency Medicine Approach, Ferrara, PC, Colucciello, SA, Marx, JA, Verdile, VP, Gibbs, MA (Eds), Mosby, St. Louis 2001. p. 331. Illustrations used with permission of Elsevier Inc. All rights reserved. Copyright &copy;2001 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35232=[""].join("\n");
var outline_f34_26_35232=null;
var title_f34_26_35233="Yolk sac 2";
var content_f34_26_35233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Yolk sac (transvaginal ultrasound)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal sagittal image shows a clear yolk sac (arrow) within the sac, diagnostic of an IUP.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tejas S Mehta, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35233=[""].join("\n");
var outline_f34_26_35233=null;
var title_f34_26_35234="Normal cord insertion by U-S";
var content_f34_26_35234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal cord insertion of a 23 1/7 weeks fetus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35234=[""].join("\n");
var outline_f34_26_35234=null;
var title_f34_26_35235="Pseudoxanthoma elasticum neck 2";
var content_f34_26_35235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudoxanthoma elasticum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Symmetric, confluent, yellow papules and redundant skin folds are present in this 38-year-old woman. The characteristic plucked chicken skin changes on the neck of patients with pseudoxanthoma elasticum are seen. An eye examination showed the characteristic angioid streaks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Rakhesh SV, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35235=[""].join("\n");
var outline_f34_26_35235=null;
var title_f34_26_35236="Methenamine and sodium acid phosphate: Patient drug information";
var content_f34_26_35236=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methenamine and sodium acid phosphate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/14/31971?source=see_link\">",
"     see \"Methenamine and sodium acid phosphate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F554012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Uroqid-Acid&reg; No. 2",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691486",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat a bladder infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methenamine and sodium acid phosphate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703621",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High phosphate levels in your blood, very bad fluid loss, very bad kidney disease, very bad liver disease, or on a low-salt or salt-free diet.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696851",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take aspirin, antacids, or drugs that raise the pH of the urine while on this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698573",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may need to check the acid content (pH) of your urine using a dipstick test.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid citrus fruits, dairy products, and some veggies while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696713",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some types of water pills may lower the effects of this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697974",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Confusion.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697915",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bone or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bladder pain or pain when passing urine or change in how much urine is passed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698174",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More thirst.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11350 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35236=[""].join("\n");
var outline_f34_26_35236=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F554012\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015008\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015007\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015012\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015013\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015015\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015010\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015011\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015016\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015017\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/14/31971?source=related_link\">",
"      Methenamine and sodium acid phosphate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_26_35237="Dientamoeba fragilis";
var content_f34_26_35237=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dientamoeba fragilis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/26/35237/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/26/35237/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/26/35237/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/26/35237/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/26/35237/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/26/35237/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/26/35237/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/26/35237/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 8, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dientamoeba fragilis is an anaerobic intestinal protozoan parasite. Historically, this organism was amongst a group of enteric protozoan parasites beginning with Giardia lamblia that were initially believed to be commensals and not capable of causing symptomatic illness. As more information became available and antimicrobial agents were developed with activity against these parasites, it became clear that D. fragilis is an active infection, although not always symptomatic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/14/39143?source=see_link\">",
"     \"Blastocystis species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10243?source=see_link\">",
"     \"Nonpathogenic enteric protozoa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the capacity of D. fragilis to cause symptomatic intestinal illness is increasingly recognized, there are a number of uncertainties surrounding D. fragilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. How uniformly infection with this parasite causes symptoms is not known, and indeed there has been past controversy over whether the organism can actually cause diarrhea as a single pathogen. Moreover, the means by which this parasite is transmitted has not been fully defined. Finally, the diagnostic recognition of this parasite in fecal examinations requires specific processing and expertise; thus, it is possible that many infections with D. fragilis may go undiagnosed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although initially identified as an amoeba, ultrastructural, immunologic and genetic analyses place this organism in the family of protozoan flagellates, which includes Trichomonas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Unlike other intestinal protozoan organisms that have both trophozoite and hardy cyst stages, Dientamoeba fragilis apparently exist only as trophozoites. Trophozoites measure 7 to 12 micrometers in diameter, contain one or two nuclei, lack flagellae, and are minimally motile.",
"   </p>",
"   <p>",
"    There is genetic evidence for at least two variants of D. fragilis. However, it is yet unknown if these two differ in their pathogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections with Dientamoeba fragilis undoubtedly are acquired by the fecal-oral route, but how fragile trophozoites survive outside of the body and do not succumb to stomach acid following ingestion is unknown (",
"    <a class=\"graphic graphic_figure graphicRef75072 \" href=\"mobipreview.htm?2/63/3063\">",
"     figure 1",
"    </a>",
"    ). Some earlier investigators suggested that trophozoites might survive within and be ingested with the eggs of the pinworm, Enterobius vermicularis. While this might explain coinfections in some children, it is not likely to explain most D. fragilis infections. In addition, some studies have specifically failed to find a correlation between D. fragilis and Enterobius vermicularis infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2583?source=see_link\">",
"     \"Enterobiasis and trichuriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    D. fragilis is distributed globally; the prevalence varies with geography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/6-14\">",
"     6-14",
"    </a>",
"    ]. In series from different countries, D. fragilis was detected in approximately 5 percent of stool samples submitted for diagnostic examination in the United States and Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/5,6,15\">",
"     5,6,15",
"    </a>",
"    ], 5 percent in the Sultanate of Oman [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/9\">",
"     9",
"    </a>",
"    ], and 8 percent in The Netherlands among patients with diarrhea lasting more than a week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/10\">",
"     10",
"    </a>",
"    ]. In the United States, D. fragilis has been detected in returned missionaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/12\">",
"     12",
"    </a>",
"    ] and patients with traveler's diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In these and subsequent analyses, it has been noted that many diagnostic laboratories probably lack the requisite procedures to detect D. fragilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Thus, the prevalence of D. fragilis is probably underestimated. In a report from Ottawa, Canada, 91 percent of healthy children had detectable serum antibodies to D. fragilis, suggesting that mild or subclinical infections were common during childhood (though cross reactivity is possible) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to geography, other factors may favor D. fragilis infection. However, the data from different regions are conflicting as to whether infection is more common in females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/17\">",
"     17",
"    </a>",
"    ] or males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. It is also unclear whether or not there is seasonal variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period prior to the onset of symptoms following infection is unknown, as is the proportion of infected people who remain asymptomatic. The parasite localizes in the colon and can cause colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/20\">",
"     20",
"    </a>",
"    ]. Common symptoms include abdominal pain, flatulence, acute and recurrent diarrhea, or loose stools [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/2,5,7,17,18,20,21\">",
"     2,5,7,17,18,20,21",
"    </a>",
"    ]. In one review most patients presented with diarrhea and abdominal pain, frequently lasting longer than a duration of two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/15\">",
"     15",
"    </a>",
"    ]. In one study of Turkish patients infected with Dientamoeba fragilis, symptoms included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal pain &mdash; 81 percent",
"     </li>",
"     <li>",
"      Diarrhea &mdash; 72 percent",
"     </li>",
"     <li>",
"      Anorexia &mdash; 16 percent",
"     </li>",
"     <li>",
"      Fatigue &mdash; 9 percent",
"     </li>",
"     <li>",
"      Nausea &mdash; 6 percent",
"     </li>",
"     <li>",
"      Weight loss &mdash; 3 percent",
"     </li>",
"     <li>",
"      Vomiting &mdash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abdominal pain and diarrhea attributable to D. fragilis infections may persist for several years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/2,5,7,9,18,21\">",
"     2,5,7,9,18,21",
"    </a>",
"    ]. D. fragilis infection may be observed in some patients fulfilling criteria for irritable bowel syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22455?source=see_link\">",
"     \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral blood eosinophilia may accompany D. fragilis infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], and an eosinophil-enriched colitis due to D. fragilis infection may be mistaken for allergic colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/20\">",
"     20",
"    </a>",
"    ]. The presence of eosinophilia in this infection is in striking contrast to disease caused by other intestinal protozoa, with the exception of Isospora belli infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30405?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24745?source=see_link\">",
"     \"Approach to the patient with eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis rests with detecting Dientamoeba fragilis trophozoites in microscopic examinations of appropriately fixed and stained stool samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/2\">",
"     2",
"    </a>",
"    ]. Trophozoites are fragile and are not detectable on wet mounts, iodine-stained samples, or formalin-ethyl acetate concentrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, fixation of stool samples in polyvinyl alcohol fixative, sodium acetate-acetic acid-formalin fixative, or Schaudinn's fixative is necessary as is the use of permanent trichrome staining [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/8\">",
"     8",
"    </a>",
"    ]. Examination of formed, as well as watery, stools increases the diagnostic yield [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Giemsa-stained fecal smears may be helpful in detecting D. fragilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/23\">",
"     23",
"    </a>",
"    ]. There are no available D. fragilis immunofluorescent or antigen assays that can be used in lieu of conventional microscopic evaluation. Specific cultivation methods have been shown effective in the detection of fecal D. fragilis, but are not commonly available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/2,24,25\">",
"     2,24,25",
"    </a>",
"    ]. Conventional and real time polymerase chain reaction (PCR) methods have been developed that have significantly higher specificities and sensitivities than microscopy, but these are not uniformly available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/2,26-29\">",
"     2,26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratories that optimally fix and stain stools have substantially higher yields in detecting D. fragilis infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/8\">",
"     8",
"    </a>",
"    ]. While many infections can be diagnosed with a single stool exam, the ability to confirm D. fragilis trophozoites increases by approximately 30 percent if three serial stool examinations are performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/8,30\">",
"     8,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections with Dientamoeba fragilis should be treated when the organism is found as a sole pathogen in stool samples from patients with abdominal pain or diarrhea lasting for more than one week.",
"   </p>",
"   <p>",
"    No large scale, randomized, controlled trials have been performed to assess the effect of various antimicrobial agents in patients infected with D. fragilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/31\">",
"     31",
"    </a>",
"    ]. There are several regimens that may be used to treat D. fragilis infections including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"       Paromomycin",
"      </a>",
"      (25 to 35",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses for seven days)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      (500 to 750 mg three times a day for 10 days)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/38/21091?source=see_link\">",
"       Iodoquinol",
"      </a>",
"      (650 mg three times a day for 20 days)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    was previously included as a therapeutic option in the Medical Letter guide to treatment of parasitic infections, but was removed from the 2010 version [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/32\">",
"     32",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/38/21091?source=see_link\">",
"     Iodoquinol",
"    </a>",
"    has traditionally been used quite commonly, but its availability is declining. Despite lack of randomized controlled trial data, the literature is suggestive of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    as a more efficacious agent than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/15,33\">",
"     15,33",
"    </a>",
"    ]. Combination therapy may also be effective; further study is needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/15,33\">",
"     15,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058301631\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , other nitroimidazole agents with potential efficacy include secnidazole, ornidazole and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Secnidazole was evaluated in a study of 35 Turkish patients with D. fragilis infection; in all but one patient the organism was eradicated with a single dose of secnidazole, suggesting that secnidazole is effective in achieving parasitological and clinical cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ornidazole (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    single dose for children and 2 g single dose for adults) was superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    in a randomized trial of 112 Turkish patients, with respect to parasitologic cure (92.9 versus 69.6 percent, p 0.001) and clinical cure (96.4 versus 76.8 percent, p 0.001) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35237/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"     Tinidazole",
"    </a>",
"    (2 g single dose) is more widely available than the above agents; use of this agent is reasonable although data are limited. It may be effective in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    or other agents; further study is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since knowledge is currently lacking about how Dientamoeba fragilis infections are transmitted, there are no specific guidelines on measures to prevent acquisition of infection with this parasite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18561528\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dientamoeba fragilis is an anaerobic intestinal protozoan parasite. It is a flagellate that produces trophozoites; cysts have not been identified. Infection may be symptomatic or asymptomatic. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection is transmitted by the fecal-oral route. D. fragilis is distributed globally but the prevalence varies with geography. Since many diagnostic laboratories lack the requisite procedures for detection, the prevalence is probably underestimated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incubation period and proportion of asymptomatic infected individuals are unknown. The parasite localizes in the colon and can cause colitis. Common symptoms include abdominal pain and acute and recurrent diarrhea. D. fragilis may present with peripheral eosinophilia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eosinophilic colitis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is made via detection of D. fragilis trophozoites in microscopic examinations of appropriately fixed and stained stool samples. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is warranted when the organism is found as a sole pathogen in stool samples in the setting of abdominal pain or diarrhea lasting more than one week. The optimal therapy is uncertain; we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"       paromomycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/1\">",
"      Weiss LM, Keohane EM. The uncommon gastrointestinal Protozoa: Microsporidia, Blastocystis, Isospora, Dientamoeba, and Balantidium. Curr Clin Top Infect Dis 1997; 17:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/2\">",
"      Johnson EH, Windsor JJ, Clark CG. Emerging from obscurity: biological, clinical, and diagnostic aspects of Dientamoeba fragilis. Clin Microbiol Rev 2004; 17:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/3\">",
"      Silberman JD, Clark CG, Sogin ML. Dientamoeba fragilis shares a recent common evolutionary history with the trichomonads. Mol Biochem Parasitol 1996; 76:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/4\">",
"      Johnson JA, Clark CG. Cryptic genetic diversity in Dientamoeba fragilis. J Clin Microbiol 2000; 38:4653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/5\">",
"      Stark D, Beebe N, Marriott D, et al. Prospective study of the prevalence, genotyping, and clinical relevance of Dientamoeba fragilis infections in an Australian population. J Clin Microbiol 2005; 43:2718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/6\">",
"      Kappus KD, Lundgren RG Jr, Juranek DD, et al. Intestinal parasitism in the United States: update on a continuing problem. Am J Trop Med Hyg 1994; 50:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/7\">",
"      Girginkardeler N, Cokun S, C&uuml;neyt Balciolu I, et al. Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole. Clin Microbiol Infect 2003; 9:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/8\">",
"      Grendon JH, Digiacomo RF, Frost FJ. Dientamoeba fragilis detection methods and prevalence: a survey of state public health laboratories. Public Health Rep 1991; 106:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/9\">",
"      Windsor JJ, Rafay AM, Shenoy AK, Johnson EH. Incidence of Dientamoeba fragilis in faecal samples submitted for routine microbiological analysis. Br J Biomed Sci 1998; 55:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/10\">",
"      van Gool T, Dankert J. [3 emerging protozoal infections in The Netherlands: Cyclospora, Dientamoeba, and Microspora infections]. Ned Tijdschr Geneeskd 1996; 140:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/11\">",
"      Oyofo BA, Peruski LF, Ismail TF, et al. Enteropathogens associated with diarrhea among military personnel during Operation Bright Star 96, in Alexandria, Egypt. Mil Med 1997; 162:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/12\">",
"      McQuay RM. Parasitologic studies in a group of furloughed missionaries. I. Intestinal protozoa. Am J Trop Med Hyg 1967; 16:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/13\">",
"      Millet VE, Spencer MJ, Chapin MR, et al. Intestinal protozoan infection in a semicommunal group. Am J Trop Med Hyg 1983; 32:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/14\">",
"      Stark D, Beebe N, Marriott D, et al. Dientamoeba fragilis as a cause of travelers' diarrhea: report of seven cases. J Travel Med 2007; 14:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/15\">",
"      Stark D, Barratt J, Roberts T, et al. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg 2010; 82:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/16\">",
"      Chan F, Stewart N, Guan M, et al. Prevalence of Dientamoeba fragilis antibodies in children and recognition of a 39 kDa immunodominant protein antigen of the organism. Eur J Clin Microbiol Infect Dis 1996; 15:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/17\">",
"      Grendon JH, DiGiacomo RF, Frost FJ. Descriptive features of Dientamoeba fragilis infections. J Trop Med Hyg 1995; 98:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/18\">",
"      Norberg A, Nord CE, Eveng&aring;rd B. Dientamoeba fragilis--a protozoal infection which may cause severe bowel distress. Clin Microbiol Infect 2003; 9:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/19\">",
"      Lagac&eacute;-Wiens PR, VanCaeseele PG, Koschik C. Dientamoeba fragilis: an emerging role in intestinal disease. CMAJ 2006; 175:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/20\">",
"      Cuffari C, Oligny L, Seidman EG. Dientamoeba fragilis masquerading as allergic colitis. J Pediatr Gastroenterol Nutr 1998; 26:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/21\">",
"      Preiss U, Ockert G, Broemme S, Otto A. On the clinical importance of Dientamoeba fragilis infections in childhood. J Hyg Epidemiol Microbiol Immunol 1991; 35:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/22\">",
"      Yakoob J, Jafri W, Beg MA, et al. Blastocystis hominis and Dientamoeba fragilis in patients fulfilling irritable bowel syndrome criteria. Parasitol Res 2010; 107:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/23\">",
"      Crotti D, D'Annibale ML, Fonzo G, et al. Dientamoeba fragilis is more prevalent than Giardia duodenalis in children and adults attending a day care centre in Central Italy. Parasite 2005; 12:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/24\">",
"      Windsor JJ, Macfarlane L. Irritable bowel syndrome: the need to exclude Dientamoeba fragilis. Am J Trop Med Hyg 2005; 72:501; author reply 501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/25\">",
"      Windsor JJ, Macfarlane L, Hughes-Thapa G, et al. Detection of Dientamoeba fragilis by culture. Br J Biomed Sci 2003; 60:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/26\">",
"      Stark D, Beebe N, Marriott D, et al. Detection of Dientamoeba fragilis in fresh stool specimens using PCR. Int J Parasitol 2005; 35:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/27\">",
"      Stark D, Beebe N, Marriott D, et al. Evaluation of three diagnostic methods, including real-time PCR, for detection of Dientamoeba fragilis in stool specimens. J Clin Microbiol 2006; 44:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/28\">",
"      Stark D, Al-Qassab SE, Barratt JL, et al. Evaluation of multiplex tandem real-time PCR for detection of Cryptosporidium spp., Dientamoeba fragilis, Entamoeba histolytica, and Giardia intestinalis in clinical stool samples. J Clin Microbiol 2011; 49:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/29\">",
"      Calderaro A, Gorrini C, Montecchini S, et al. Evaluation of a real-time polymerase chain reaction assay for the detection of Dientamoeba fragilis. Diagn Microbiol Infect Dis 2010; 67:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/30\">",
"      Hiatt RA, Markell EK, Ng E. How many stool examinations are necessary to detect pathogenic intestinal protozoa? Am J Trop Med Hyg 1995; 53:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/31\">",
"      Stark DJ, Beebe N, Marriott D, et al. Dientamoebiasis: clinical importance and recent advances. Trends Parasitol 2006; 22:92.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections, 2nd Ed, The Medical Letter, Inc, New Rochelle, NY 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/33\">",
"      Vandenberg O, Souayah H, Mouchet F, et al. Treatment of Dientamoeba fragilis infection with paromomycin. Pediatr Infect Dis J 2007; 26:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35237/abstract/34\">",
"      Kurt O, Girginkardeler N, Balciolu IC, et al. A comparison of metronidazole and single-dose ornidazole for the treatment of dientamoebiasis. Clin Microbiol Infect 2008; 14:601.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5720 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35237=[""].join("\n");
var outline_f34_26_35237=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18561528\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1058301631\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18561528\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5720\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5720|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/63/3063\" title=\"figure 1\">",
"      Dientamoeba fragilis life cycle",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/14/39143?source=related_link\">",
"      Blastocystis species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2583?source=related_link\">",
"      Enterobiasis and trichuriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30405?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10243?source=related_link\">",
"      Nonpathogenic enteric protozoa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_26_35238="Osteoblastic osteosarcoma";
var content_f34_26_35238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F87011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F87011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Osteoblastic osteosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 197px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic appearance of an osteoblastic osteosarcoma with eosinophilic osteoid material (yellow arrows) produced by pleomorphic malignant osteoblasts with occasional malignant osteoblastic giant cells (white arrowhead). Note variable amounts of osteoid production.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M John Hicks, DDS, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35238=[""].join("\n");
var outline_f34_26_35238=null;
var title_f34_26_35239="Treatment of Graves' orbitopathy (ophthalmopathy)";
var content_f34_26_35239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Graves' orbitopathy (ophthalmopathy)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/26/35239/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/26/35239/contributors\">",
"     Terry F Davies, MD, FRCP, FACE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/26/35239/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/26/35239/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/26/35239/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/26/35239/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/26/35239/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graves' orbitopathy (ophthalmopathy, GO) is an autoimmune disease of the retroorbital tissues. This topic review will provide an overview of the treatment of this disorder; its pathogenesis and clinical features are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3432?source=see_link\">",
"     \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of Graves' orbitopathy is variable and must be considered in the context of concomitant antithyroid therapy. In some patients, as an example, orbitopathy changes little for many years. In others, it may worsen or improve, or, in a few patients, follow a course characterized by exacerbations and remissions. These variations make it especially difficult to reach conclusions about the efficacy of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study, as an example, evaluated 59 patients with untreated eye disease who had not received any immunosuppressive or surgical treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/2\">",
"     2",
"    </a>",
"    ]. They had all received an antithyroid drug, which may be immunosuppressive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. As assessed using a well-characterized activity index, 66 percent of these patients improved during the first 12 months, and only 8 percent had deterioration in their eye disease.",
"   </p>",
"   <p>",
"    Treatment of patients with Graves' orbitopathy has three components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reversal of hyperthyroidism, if present",
"     </li>",
"     <li>",
"      Symptomatic treatment",
"     </li>",
"     <li>",
"      Treatment with a glucocorticoid,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      orbital irradiation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      orbital decompression surgery to reduce inflammation in the periorbital tissues",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    has not been proven to be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    , a somatostatin analog, does not appear to improve disease activity or severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    , an anti-B cell monoclonal antibody, has been reported to be as effective as glucocorticoids without the glucocorticoid-related side effects, and is discussed further below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of these therapies will be reviewed first, followed by an outline of the regimen that we usually use to treat patients with this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTITHYROID TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The question of whether antithyroid treatment influences Graves' orbitopathy is complex. There are two major influences at work: the reduction in thyroid hormone secretion and the potential direct effects of the therapy. Reducing thyroid hormone secretion does not improve the pathology of Graves' ophthalmopathy, although it does decrease eyelid retraction and stare. However, hypothyroidism and its concomitant fluid retention may have an adverse effect on ophthalmopathy and, therefore, should be avoided. More important is the influence of antithyroid therapy on the disease.",
"   </p>",
"   <p>",
"    Graves' orbitopathy may worsen or first become apparent after treatment of hyperthyroidism, depending upon the treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. A randomized trial, as an example, evaluated 168 patients with Graves' hyperthyroidism, 22 of whom had preexisting orbitopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/10\">",
"     10",
"    </a>",
"    ]. Correction of the hyperthyroidism was associated with new onset of orbitopathy in 22 (15 percent) and worsening of the orbitopathy in 8 of 22 (36 percent). The worsening was manifested in most patients by an extra 1 to 2 mm of proptosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surgery or antithyroid drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial effect of antithyroid therapy on orbitopathy varies with the type of treatment. Subtotal thyroidectomy and antithyroid drugs do not appear to have a negative influence on the course of orbitopathy. As examples, orbitopathy did not appear or worsen any more often in patients treated by subtotal thyroidectomy or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    in the randomized trial described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/10\">",
"     10",
"    </a>",
"    ], or in a case-control study in which 30 patients who underwent near-total thyroidectomy and 60 patients who were treated with methimazole were followed for one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/14\">",
"     14",
"    </a>",
"    ]. In the latter study, one patient in the surgery group had worsening of preexisting orbitopathy and two patients in the methimazole group had new onset of orbitopathy. These two treatments are usually followed by a fall in serum antithyroid antibody concentrations, suggesting a waning of autoimmunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a patient with Graves' hyperthyroidism is treated with surgery, a near total thyroidectomy should be considered, as it may be associated with less progression of proptosis postoperatively than a subtotal thyroidectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/15\">",
"     15",
"    </a>",
"    ]. However, patients who had a total thyroidectomy versus a subtotal thyroidectomy when compared after three years were found to have similar improvement in orbitopathy (and surgical complications were higher in the total thyroidectomy group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/16\">",
"     16",
"    </a>",
"    ]. Of note, total thyroidectomy results in the total disappearance of antibodies to all major thyroid antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Radioiodine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that radioiodine therapy can cause the development or worsening of Graves' orbitopathy more often than antithyroid drug therapy or surgery. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12410?source=see_link&amp;anchor=H30632428#H30632428\">",
"     \"Radioiodine in the treatment of hyperthyroidism\", section on 'Radioiodine and ophthalmopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3908344\">",
"    <span class=\"h2\">",
"     Local measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local measures including eye shades,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    (saline eye drops), and raising the head of the bed at night often lead to sufficient relief of eye symptoms and no additional treatment is needed. Photophobia and sensitivity to wind or cold air are often relieved by use of dark glasses and instillation of artificial tears every two to three hours during the day and of lubricants, such as 1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    drops, at night.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3908336\">",
"    <span class=\"h2\">",
"     Selenium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     Selenium",
"    </a>",
"    is a trace mineral with a role in multiple biologic functions. More than 30 selenoproteins have been identified, of which the best known are the four forms of glutathione peroxidase, which are important in antioxidant defense and iodo-thyronine deiodinase 2 (three forms), which serves as a catalyst for production of thyroid hormone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39226?source=see_link&amp;anchor=H48#H48\">",
"     \"Overview of dietary trace minerals\", section on 'Selenium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     Selenium",
"    </a>",
"    supplementation may decrease inflammatory activity in patients with autoimmune thyroiditis, as evidenced by a fall in thyroid antibody levels, and may also reduce the risk of postpartum thyroiditis in women who are positive for thyroid peroxidase (TPO) antibodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/248?source=see_link&amp;anchor=H9#H9\">",
"     \"Postpartum thyroiditis\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     Selenium",
"    </a>",
"    may improve symptoms in patients with mild Graves&rsquo; ophthalmopathy, as illustrated by the results of a randomized trial of selenium (100 mcg twice daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    (600 mg twice daily), or placebo in 159 patients from a region in which selenium levels are marginally decreased. These patients had at least one sign of mild orbitopathy (chemosis, mild to moderate eye lid swelling, exophthalmos &le;22 mm) and disease duration of &lt;18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/18\">",
"     18",
"    </a>",
"    ]. All patients were euthyroid while taking thionamides or, less commonly, after thyroidectomy or radioiodine treatment. After six months of treatment, eyelid aperture (37 versus 12 percent) and soft-tissue signs (43 versus 32 percent) significantly improved in patients taking selenium versus placebo. Compared with placebo, selenium also significantly improved quality of life (both visual functioning and appearance scores), as assessed by the Graves&rsquo; Ophthalmopathy Quality of Life Questionnaire (GO-QOL). Evaluation at 12 months confirmed the findings at six months. Neither placebo nor pentoxifylline improved quality of life measures.",
"   </p>",
"   <p>",
"    It is uncertain if such mild changes are of practical importance in the real life situation. Although there were no adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    treatment in any of the studies reported to date, more work is required before recommending this treatment for the many patients with mild eye involvement. As an example, it is uncertain if selenium would benefit individuals with mild Graves&rsquo; orbitopathy who are from selenium-rich regions (eg, most of the United States).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MORE AGGRESSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing proptosis and worsening soft tissue signs may warrant more vigorous therapy. In our experience, diuretics are not helpful. Nonsteroidal antiinflammatory drugs, including COX-2 inhibitors, may be helpful in patients with mild symptoms of eye irritation. Glucocorticoids, given orally or intravenously, are the primary treatment for severe Graves' orbitopathy. Radiation and surgical decompression can also be used in selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    , given orally, has gained wide acceptance as effective treatment for patients with severe Graves' orbitopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/5,11\">",
"     5,11",
"    </a>",
"    ].Worsening orbitopathy may respond favorably and rapidly to oral prednisone therapy via its antiinflammatory and immunosuppressive actions.",
"   </p>",
"   <p>",
"    The optimal dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is uncertain. Some clinicians initiate therapy with a high dose, such as 100",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    However, doses of 30 to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    appear to be as effective and have fewer side effects. Improvement usually occurs within four weeks. About one-half of patients have a good response to prednisone by the end of six months; those patients with less muscle swelling are more likely to respond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/19\">",
"     19",
"    </a>",
"    ]. However, given the many side effects of prolonged high-dose prednisone treatment, other treatments should be considered if the patient does not respond in four to six weeks. If a good response occurs, the daily dose should be decreased to the lowest dose at which improvement is maintained.",
"   </p>",
"   <p>",
"    In some patients, the eye disease worsens when the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is reduced. These are the patients who require therapy to prevent the side effects of the glucocorticoid from becoming more dangerous than the eye disease. In particular, bisphosphonate therapy should be initiated early in patients receiving high-dose prednisone therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous glucocorticoid pulse therapy has also been used and may have the advantage of fewer side effects than high oral doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/1,21,22\">",
"     1,21,22",
"    </a>",
"    ]. In a trial of 70 euthyroid patients with untreated, severe ophthalmopathy randomly assigned to receive once weekly intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (0.5 g, then 0.25 g, weekly for six weeks each) or oral prednisone (100 mg per day, tapering by 10 mg per week), the following results were seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      At three months, 27 of 35 patients (77 percent) in the intravenous group had a treatment response compared with 18 of 35 (51 percent) in the oral group",
"     </li>",
"     <li>",
"      Improvements over baseline for visual acuity, chemosis, and quality of life were greater in the intravenous group",
"     </li>",
"     <li>",
"      Additional treatment was required less frequently in the intravenous group",
"     </li>",
"     <li>",
"      Adverse events were less frequent with intravenous glucocorticoids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantage of intravenous over oral glucocorticoid therapy was also demonstrated in a meta-analysis of four trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/24\">",
"     24",
"    </a>",
"    ]. Intravenous glucocorticoids were significantly better in reducing clinical activity scores; the advantage was mostly due to improvements in patients with severe orbitopathy. Adverse events were more common in patients receiving oral therapy and high doses have been seen to induce liver failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H331003\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports have indicated that some patients with severe Graves&rsquo; orbitopathy may respond dramatically to B cell depletion induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , which is a monoclonal antibody directed against the B cell CD20 molecule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/8,9,25,26\">",
"     8,9,25,26",
"    </a>",
"    ]. Rituximab induces a fall in TSH receptor antibody levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/27\">",
"     27",
"    </a>",
"    ] and depletion of B cells in the retroorbital tissues, not just the periphery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/28\">",
"     28",
"    </a>",
"    ]. Although high doses of this antibody may be associated with severe side effects from the profound immunosuppression that ensues, it is likely that much lower doses may be effective in Graves&rsquo; orbitopathy and allow such effects to be avoided. This approach to the treatment of severe eye disease is currently undergoing larger trials; preliminary results from these trials suggest efficacy in some, but not all, patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     External orbital radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiotherapy kills retroorbital T cells. The value of orbital radiation is controversial. In two trials it was more effective than glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/21,29\">",
"     21,29",
"    </a>",
"    ]. Results differed in two trials comparing orbital radiation to sham-irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However, in a meta-analysis of three trials, orbital radiation was no better than sham radiation for improvement in clinical activity score, but was better for diplopia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trials of combined radiation and glucocorticoid therapy have suggested that the combination may be more effective than either alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/24,32,33\">",
"     24,32,33",
"    </a>",
"    ]. In a randomized trial of 82 patients with Graves' ophthalmopathy treated with high-dose intravenous or oral glucocorticoid (combined with orbital radiation), the intravenous route was more effective, better tolerated, and associated with fewer side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, if combined therapy is used, intravenous glucocorticoid may be preferable.",
"   </p>",
"   <p>",
"    Orbital radiation has been thought to be most effective in ameliorating the inflammatory manifestations of ophthalmopathy, with little or no change in proptosis and muscle function. However, in one randomized trial radiotherapy was effective in improving eye muscle motility and decreasing the severity of diplopia, but it did not prevent subsequent worsening of ophthalmopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/35\">",
"     35",
"    </a>",
"    ]. The usual dose is 2000 rads (20 Gy), administered in 10 doses of 200 rads (2 Gy) over two weeks.",
"   </p>",
"   <p>",
"    Potential side effects reported in 204 patients with a mean follow-up of 11 years included: cataracts in 18 percent treated with a cobalt unit and 8 percent treated by linear accelerator; compared with the general population the rates were not significantly elevated in patients under age 60 years; mild retinopathy in 14 percent of patients with diabetes and hypertension, 3 percent of patients with hypertension alone, and none in patients with diabetes alone; and no secondary tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/36\">",
"     36",
"    </a>",
"    ]. Transient blindness can also occur due to injury to the optic nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15478313\">",
"    <span class=\"h2\">",
"     Other medical therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15478321\">",
"    <span class=\"h3\">",
"     Somatostatin analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin analogs have been explored as a potential therapy for Graves' ophthalmopathy, based upon the observations that orbital fibroblasts have somatostatin receptors and the activity of orbitopathy correlates with activity on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    scintigrams. One randomized, placebo-controlled trial of a long-acting octreotide preparation reported improvement in clinical activity scores and median lid fissure width with octreotide compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/38\">",
"     38",
"    </a>",
"    ]. In contrast, two other similar trials reported limited benefit with octreotide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In a metaanalysis of four trials, somatostatin analogs resulted in a slightly lower clinical activity score than placebo, but had no advantages for other important outcomes (diplopia, proptosis, lid aperture) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/24\">",
"     24",
"    </a>",
"    ]. Octreotide has no role in the routine treatment of Graves' ophthalmopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Orbital decompression surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major indications for orbital decompression in Graves' orbitopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If glucocorticoid therapy or orbital irradiation fails to halt progression of the orbitopathy",
"     </li>",
"     <li>",
"      If loss of vision is threatened either by ulceration or infection of the cornea or by changes in the retina or optic nerve",
"     </li>",
"     <li>",
"      For cosmetic correction of severe proptosis &ndash; in this case, decompression surgery should be avoided for as long as possible until the disease calms down under corticosteroid suppression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The orbit may be decompressed by removing the lateral wall, the roof, or the medial wall and the floor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Our experience has been with the last procedure, known as transantral decompression, in which the surgeon removes the floor and medial wall of the orbit to allow decompression. In addition, it does not leave a scar on the face, and avoids craniotomy.",
"   </p>",
"   <p>",
"    An excellent result can usually be achieved, with substantial reduction in proptosis and edema. However, diplopia usually does not improve and may worsen, so that eye muscle surgery is almost always needed later.",
"   </p>",
"   <p>",
"    In a series of 78 patients who had transantral or endonasal decompression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proptosis was reduced by 4.4 to 4.7 mm (left and right eyes)",
"     </li>",
"     <li>",
"      Visual acuity improved in 44 to 55 percent and worsened in 18 to 20 percent",
"     </li>",
"     <li>",
"      Diplopia persisted in 50 percent, but was improved in 54 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Timing of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, clinical outcome appears to be better if decompression surgery is performed after rather than before glucocorticoid therapy. This was illustrated in a trial of 15 patients randomized to initial intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or orbital decompression. In the group of patients who initially received surgery, 83 percent subsequently required methylprednisolone and some also required orbital irradiation, while 56 percent of the patients initially treated with methylprednisolone required surgery or orbital irradiation. The authors concluded that initial therapy should be with methylprednisolone pulse therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other operations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fat decompression surgery, removing the retroorbital adipose tissue, has been performed for many years and can produce a cosmetic correction in patients with moderate Graves&rsquo; orbitopathy and significant proptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/44\">",
"     44",
"    </a>",
"    ]. Bilateral lateral tarsorrhaphy may be performed to minimize or prevent corneal damage in patients who have severe proptosis and cannot close their eyes. Surgical recession of Muller's muscle and the levator will correct upper lid retraction. However, decompression surgery is preferable for both of these problems because it is more effective both functionally and cosmetically. Occasional patients require plastic surgery to correct marked periorbital edema. Many others have chosen to have cosmetic correction of relatively mild edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUGGESTED APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Graves' orbitopathy should be treated according to the severity of their eye disease, keeping in mind its natural history. Most patients have mild disease, and approximately 65 percent of them have no progression during follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35239/abstract/2\">",
"     2",
"    </a>",
"    ]. Those patients with more severe ophthalmopathy may also have no progression, and in both groups the inflammatory manifestations of the disorder (eye irritation and conjunctival and periorbital edema) tend to subside. There is little change in proptosis, but the patients' eyes look more normal (and feel better).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mild symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;For these patients only local measures are required, including eye shades,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    , avoiding sleeping on the face, and raising the head of the bed. Some studies suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    (100 mcg twice daily) for six months may improve soft tissue swelling and quality of life measures, but these reports require confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Red eyes and progressive symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the patient with inflamed eyes and increasing diplopia or proptosis, a trial of oral glucocorticoid therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for four weeks) should be initiated. Higher doses may be required if this dose is ineffective. If high-dose therapy is contraindicated or cannot be tolerated, external radiation may be given if edema predominates. Local measures should be used along with these major forms of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Loss of vision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close and coordinated observation of the effects of medical therapy and the progress of the disease is necessary to determine whether and when a surgical approach to treatment is needed in the patient with visual loss. Decompression surgery almost invariably halts the progress of the disease and preserves vision if performed in time. Threatened loss of vision, often preceded by loss of color vision, is a",
"    <strong>",
"     medical emergency",
"    </strong>",
"    . Such a patient should receive immediate glucocorticoid therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , 4 mg intramuscularly, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , 100 mg orally) and should be hospitalized for possible urgent orbital decompression surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17628836\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with Graves' orbitopathy should be treated according to the severity of their eye disease, keeping in mind that most patients have mild disease and do not have progression during follow-up. The treatment of patients with Graves' orbitopathy includes reversal of hyperthyroidism (if present), relief of symptoms, and reduction of inflammation in the periorbital tissues. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Graves' orbitopathy may worsen or first become apparent after treatment of hyperthyroidism, depending upon the treatment. Subtotal thyroidectomy and antithyroid drugs do not appear to have a negative influence on the course of orbitopathy. However, there is increasing evidence that radioiodine therapy can cause the development or worsening of Graves' orbitopathy more often than antithyroid drug therapy or surgery. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antithyroid treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12410?source=see_link&amp;anchor=H30632428#H30632428\">",
"       \"Radioiodine in the treatment of hyperthyroidism\", section on 'Radioiodine and ophthalmopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptomatic treatment includes eye shades,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      (saline eye drops), and raising the head of the bed at night, which often lead to sufficient relief of eye symptoms. Photophobia and sensitivity to wind or cold air can be relieved by use of dark glasses. Some studies suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      (100 mcg twice daily) for six months may improve soft tissue swelling and quality of life measures, but these reports require confirmation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Symptomatic treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Suggested approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increasing proptosis and worsening soft tissue signs may warrant more vigorous therapy. Glucocorticoids, given orally or intravenously, are the primary treatment for severe Graves' orbitopathy. Radiation and surgical decompression can also be used in selected patients. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'More aggressive therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Suggested approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/1\">",
"      Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/2\">",
"      Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995; 42:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/3\">",
"      Hall R, Smith BR, Mukhtar ED. Thyroid stimulators in health and disease. Clin Endocrinol (Oxf) 1975; 4:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/4\">",
"      Weetman AP. The immunomodulatory effects of antithyroid drugs. Thyroid 1994; 4:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/5\">",
"      Wiersinga WM. Immunosuppressive treatment of Graves' ophthalmopathy. Thyroid 1992; 2:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/6\">",
"      Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2004; 89:5910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/7\">",
"      W&eacute;meau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 2005; 90:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/8\">",
"      Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006; 154:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/9\">",
"      El Fassi D, Nielsen CH, Hasselbalch HC, Heged&uuml;s L. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006; 154:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/10\">",
"      Tallstedt L, Lundell G, T&oslash;rring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992; 326:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/11\">",
"      Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/12\">",
"      Sridama V, DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 1989; 87:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/13\">",
"      Gwinup G, Elias AN, Ascher MS. Effect on exophthalmos of various methods of treatment of Graves' disease. JAMA 1982; 247:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/14\">",
"      Marcocci C, Bruno-Bossio G, Manetti L, et al. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 1999; 51:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/15\">",
"      Kurihara H. Total thyroidectomy for the treatment of hyperthyroidism in patients with ophthalmopathy. Thyroid 2002; 12:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/16\">",
"      J&auml;rhult J, Rudberg C, Larsson E, et al. Graves' disease with moderate-severe endocrine ophthalmopathy-long term results of a prospective, randomized study of total or subtotal thyroid resection. Thyroid 2005; 15:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/17\">",
"      Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003; 139:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/18\">",
"      Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves' orbitopathy. N Engl J Med 2011; 364:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/19\">",
"      Chang TC, Huang KM, Hsiao YL, et al. Relationships of orbital computed tomographic findings and activity scores to the prognosis of corticosteroid therapy in patients with Graves' ophthalmopathy. Acta Ophthalmol Scand 1997; 75:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/20\">",
"      Eastell R, Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000; 11:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/21\">",
"      Prummel MF, Wiersinga WM. Medical management of Graves' ophthalmopathy. Thyroid 1995; 5:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/22\">",
"      Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011; 96:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/23\">",
"      Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005; 90:5234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/24\">",
"      Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, et al. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab 2009; 94:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/25\">",
"      Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007; 156:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/26\">",
"      Heged&uuml;s L, Smith TJ, Douglas RS, Nielsen CH. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol (Oxf) 2011; 74:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/27\">",
"      El Fassi D, Banga JP, Gilbert JA, et al. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009; 130:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/28\">",
"      Salvi M, Vannucchi G, Campi I, et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol 2009; 131:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/29\">",
"      Prummel MF, Mourits MP, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993; 342:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/30\">",
"      Mourits MP, van Kempen-Harteveld ML, Garc&iacute;a MB, et al. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 2000; 355:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/31\">",
"      Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001; 108:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/32\">",
"      Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983; 56:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/33\">",
"      Wiersinga WM, Prummel MF. An evidence-based approach to the treatment of Graves' ophthalmopathy. Endocrinol Metab Clin North Am 2000; 29:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/34\">",
"      Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001; 86:3562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/35\">",
"      Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 2004; 89:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/36\">",
"      Marcocci C, Bartalena L, Rocchi R, et al. Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 2003; 88:3561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/37\">",
"      Nygaard B, Specht L. Transitory blindness after retrobulbar irradiation of Graves' ophthalmopathy. Lancet 1998; 351:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/38\">",
"      Stan MN, Garrity JA, Bradley EA, et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab 2006; 91:4817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/39\">",
"      Lyons CJ, Rootman J. Orbital decompression for disfiguring exophthalmos in thyroid orbitopathy. Ophthalmology 1994; 101:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/40\">",
"      Ogura JH, Thawley SE. Orbital decompression of exophthalmos. Otolaryngol Clin North Am 1980; 13:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/41\">",
"      Shorr N, Seiff SR. The four stages of surgical rehabilitation of the patient with dysthyroid ophthalmopathy. Ophthalmology 1986; 93:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/42\">",
"      Jernfors M, V&auml;lim&auml;ki MJ, Set&auml;l&auml; K, et al. Efficacy and safety of orbital decompression in treatment of thyroid-associated ophthalmopathy: long-term follow-up of 78 patients. Clin Endocrinol (Oxf) 2007; 67:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/43\">",
"      Wakelkamp IM, Baldeschi L, Saeed P, et al. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 2005; 63:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35239/abstract/44\">",
"      Garrity JA. Orbital lipectomy (fat decompression) for thyroid eye disease: an operation for everyone? Am J Ophthalmol 2011; 151:399.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7827 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F708DC0240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35239=[""].join("\n");
var outline_f34_26_35239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17628836\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTITHYROID TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surgery or antithyroid drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Radioiodine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SYMPTOMATIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3908344\">",
"      Local measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3908336\">",
"      Selenium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MORE AGGRESSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H331003\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      External orbital radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15478313\">",
"      Other medical therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15478321\">",
"      - Somatostatin analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Orbital decompression surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Timing of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other operations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUGGESTED APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mild symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Red eyes and progressive symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Loss of vision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17628836\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3432?source=related_link\">",
"      Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/248?source=related_link\">",
"      Postpartum thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12410?source=related_link\">",
"      Radioiodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_26_35240="Heel pain exercises PI";
var content_f34_26_35240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Exercises that can help with heel pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 481px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35240=[""].join("\n");
var outline_f34_26_35240=null;
var title_f34_26_35241="Sensory nerves in females";
var content_f34_26_35241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Sensory nerves in females",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 555px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35241=[""].join("\n");
var outline_f34_26_35241=null;
var title_f34_26_35242="Second malignancies after treatment of classical Hodgkin lymphoma";
var content_f34_26_35242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Second malignancies after treatment of classical Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/26/35242/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/26/35242/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/26/35242/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/26/35242/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/26/35242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/26/35242/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/26/35242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the majority of patients with Hodgkin lymphoma (formerly called Hodgkin's disease, HL) are able to achieve long-term survival free of HL, late complications of treatment have emerged as a competing cause of death and morbidity. Long-term survivors are at risk for developing second malignancies, cardiovascular disease (eg, due to anthracycline toxicity or mediastinal radiation), pulmonary disease (eg, due to radiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ), thyroid dysfunction, sterility, and other complications.",
"   </p>",
"   <p>",
"    This topic review will discuss the second malignancies that are commonly seen in patients who have been treated for HL. Other complications are presented separately, as are recommendations for the long-term follow-up of patients with HL and the risk of second malignancy after hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672644#H1167672644\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Follow-up for long-term complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28280?source=see_link\">",
"     \"Malignancy after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL OBSERVATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiotherapy for Hodgkin lymphoma (HL) have an increased risk of developing acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and solid tumors when compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These second cancers have a significant impact upon survival from HL. The relative risk of developing a second malignancy has varied greatly among studies and is dependent upon a number of patient and treatment factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Radiation dose and fields",
"     </li>",
"     <li>",
"      Chemotherapy agents and doses administered",
"     </li>",
"     <li>",
"      Patient age at treatment",
"     </li>",
"     <li>",
"      Smoking history",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these factors, certain patients may have a genetic predisposition towards developing second malignancies after treatment of HL. As an example, a genome-wide association study in survivors of HL treated with radiotherapy reported that patients with certain single nucleotide polymorphisms at chromosome 6q21 were more likely to develop a second malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/4\">",
"     4",
"    </a>",
"    ]. Further study of candidate genes in this region may reveal new data regarding the pathogenesis of second malignancies in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Relative and absolute risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid tumors account for the majority of second cancers in HL survivors, with breast, lung, and gastrointestinal cancer being the most frequent. Leukemia and non-Hodgkin lymphoma (NHL) are less common, but occur much more frequently in this population when compared with the general population (ie, high relative risk).",
"   </p>",
"   <p>",
"    The estimated overall relative risks in 11 large cohort studies were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Leukemia &mdash; 10 to 80-fold",
"     </li>",
"     <li>",
"      Non-Hodgkin lymphoma &mdash; 3 to 35-fold",
"     </li>",
"     <li>",
"      Solid tumors (lung, breast, bone, stomach, colon, thyroid, melanoma) &mdash; over twofold",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Leukemia and NHL are diseases with a low incidence in the general population; as a result, an increase in their relative risk following the treatment of HL (ie, up to 80-fold) does not translate into a high likelihood of developing leukemia or NHL. On the other hand, even though the relative risk of developing a solid tumor is lower (ie, twofold), the cumulative number of solid tumors that develop over the entire follow-up period is much higher than the number of cases of leukemia or NHL, because the incidence of solid tumors in the general population is so much higher (",
"    <a class=\"graphic graphic_table graphicRef57099 \" href=\"mobipreview.htm?1/22/1391\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absolute number of second cancers in patients with HL that may be attributable to treatment (ie, excess cases) is 40 to 90 malignancies per 10,000 patients per year (0.4 to 0.7 percent per year) (",
"    <a class=\"graphic graphic_table graphicRef57099 \" href=\"mobipreview.htm?1/22/1391\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5-11\">",
"     5-11",
"    </a>",
"    ]. Several retrospective case series have reported an actuarial risk of second cancer of 11 to 18 percent at 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]; 20 percent at 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]; and 28 percent at 25 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A combined analysis of three large studies including 6292 patients showed that, in the period of 10 or more years after first treatment, lung cancer contributed most to the absolute excess cancer risk, with 34 excess cases per 10,000 HL patients per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,7,12\">",
"     6,7,12",
"    </a>",
"    ]. NHL",
"    <span class=\"nowrap\">",
"     (28/10,000",
"    </span>",
"    per year) was second, and leukemia",
"    <span class=\"nowrap\">",
"     (10/10,000",
"    </span>",
"    per year) third. In women, breast cancer accounted for the largest absolute excess risk",
"    <span class=\"nowrap\">",
"     (40/10,000",
"    </span>",
"    per year) in 10-year survivors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect of elapsed time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elapsed time from initial treatment affects both the risk of death due to Hodgkin lymphoma (HL) and the risk of developing a second cancer.",
"   </p>",
"   <p>",
"    Most deaths due to HL occur in the first 5 to 10 years, while most of the later deaths are due to other causes (eg, cardiac, second malignancy). The cumulative incidence of mortality from HL is exceeded by all other causes after 14 years (",
"    <a class=\"graphic graphic_figure graphicRef71648 \" href=\"mobipreview.htm?35/61/36829\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Although death from HL abates with time, the absolute excess risk of mortality from other causes remains elevated, with no apparent diminution of the excess risk beyond 20 to 30 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/10,14,16,17\">",
"     10,14,16,17",
"    </a>",
"    ]. Of importance, the risk of death from HL varies according to the stage of HL at presentation with death from HL increasing with increased stage disease. As such, the time point at which death due to treatment-related complications exceeds that of death due to HL varies by stage at diagnosis.",
"   </p>",
"   <p>",
"    Different tumor types demonstrate distinct temporal patterns of development with respect to the elapsed time from initial treatment of HL. The risk of developing leukemia peaks at five to nine years post treatment, whereas solid tumors typically develop after a latency period of at least 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6\">",
"     6",
"    </a>",
"    ]. In one series, the median time to onset of acute leukemia, NHL, and solid tumors was 5, 7.3 and 12.2 years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/9\">",
"     9",
"    </a>",
"    ]. Because of this the relative and absolute excess risks in survivors at a particular time point since therapy differ greatly from those observed in the entire patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect of treatment given",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing a second cancer differs greatly depending upon the treatment administered. As an example, the development of secondary leukemia is primarily due to the use of chemotherapy that includes alkylating agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ). In contrast, the development of secondary lung cancer appears to be related to the use of radiotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy.",
"   </p>",
"   <p>",
"    Efforts have been made to shift treatment practice to chemotherapy regimens that are less carcinogenic and radiation fields and doses that limit exposure. As an example, radiation therapy fields used for HL have decreased over the years from total lymphoid irradiation to involved-field irradiation to involved-nodal irradiation. Since secondary neoplasms can take decades to develop, further long-term follow-up is required for some of these treatment adjustments before confirming a decrease in long-term toxicities.",
"   </p>",
"   <p>",
"    However, retrospective series have noted a decrease in long-term toxicities and non-HL related deaths as treatment patterns have changed to reduce the exposure of patients to radiation and certain chemotherapy agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 2498 patients treated at Stanford between 1960 and 1995, the absolute excess risk of death from causes other than HL was lower in patients treated between 1980 and 1995 compared with those treated earlier [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In our series of 1319 patients with HL, the relative risk for development of a second malignancy was significantly higher with combined chemotherapy and radiation therapy (RR 6.1) than with radiation therapy alone (RR 4.0) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/10\">",
"       10",
"      </a>",
"      ]. This risk increased with increasing radiation field size in patients who received combined modality therapy, suggesting that the risk may be reduced with smaller radiation fields, as are used in current trials of abbreviated chemotherapy and limited-field radiation therapy.",
"     </li>",
"     <li>",
"      In another series of 5798 patients with HL treated in Britain between 1963 and 2001, the relative risk of developing a second malignancy was higher with combined chemotherapy plus radiation therapy (RR 3.9) than with chemotherapy alone (RR 2.0) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/18\">",
"       18",
"      </a>",
"      ]. Among patients treated with chemotherapy alone, the excess second malignancies were leukemia, non-Hodgkin lymphoma, and lung cancer. In this population, the excess risk peaked five to nine years after chemotherapy administration and was close to baseline by 15 years. In contrast, combine chemotherapy plus radiation therapy was associated with several other types of second malignancy and the excess risk remained for 25 years or longer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This decrease in long-term toxicities with changes in treatment patterns has also been supported by studies that suggest that multivariate modeling may allow for the development of an individual risk assessment of second tumor risk after HL treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient survival after the diagnosis of a second cancer is generally poor. In our series, the five-year survival rate after the development of a second malignancy was 38 percent, with the worst prognosis seen in those developing acute leukemia or lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients who develop acute leukemia or a myelodysplastic syndrome have a two-year survival rate of approximately 10 percent, while those who develop NHL or a solid tumor have five- and 10-year survival rates of approximately 32 and 23 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8\">",
"     8",
"    </a>",
"    ]. Similarly, in another study, the median survival from diagnosis of second tumor was approximately 42 months and was especially poor in patients developing a second cancer following a HL diagnosis at the age of 40 years or older (median survival: approximately one year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Second cancers have a significant impact upon survival from HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5,8,21\">",
"     5,8,21",
"    </a>",
"    ]. The range of findings can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 20-year follow-up study of almost 1300 patients (median follow-up 9.2 years) who were treated between 1966 and 1986, the cumulative risk of dying from HL or acute treatment toxicity was 33 percent, while the risk of dying from a second cancer was 14 percent and that from all other causes was 20 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Virtually identical findings were noted in a report from the International Database on Hodgkin's Disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8\">",
"       8",
"      </a>",
"      ]. The overall probability of 20-year survival in 14,315 patients with HL who were treated between 1960 and 1987 (average follow-up 6.7 years) was 50 percent; 37 percent died from HL or acute treatment toxicity, and 10 percent died from a second cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ACUTE LEUKEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute leukemia was the first secondary malignancy to be noted in patients treated for HL because of its relatively early appearance following treatment, as well as the rarity of acute leukemia in the general population. The highest risks and the greatest number of cases occur between 5 and 10 years after initiation of treatment, usually with alkylating agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/22\">",
"     22",
"    </a>",
"    ]. This increased risk persists after 10 years, although at lower levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5,6,8,22-25\">",
"     5,6,8,22-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported incidence of acute leukemia in large series has ranged from 1.3 percent at an average follow-up of 6.7 years (0.8 percent in the subset in continuous complete remission) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8\">",
"     8",
"    </a>",
"    ] to 3.3 percent at 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7\">",
"     7",
"    </a>",
"    ]. Although the relative risk of leukemia in these patients is considerably increased compared with the general population, the relatively low cumulative risk and number of excess cases of acute leukemia has limited the study of specific risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most leukemias that occur after the treatment of HL are acute myeloid leukemia (AML) related to alkylating agent exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6-8,26-30\">",
"     6-8,26-30",
"    </a>",
"    ]. The relative risk increase associated with large-field irradiation alone is smaller [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5-7,12,22\">",
"     5-7,12,22",
"    </a>",
"    ]. The actuarial risk of leukemia at 15 years ranges from 0 to 0.6 percent among those receiving only radiation therapy to as high as 16.5 percent at 15 years in heavily treated groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7,12,31-33\">",
"     7,12,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative risk of leukemia also varies with the reference group and the type of leukemia considered. The relative risks in chemotherapy-treated patients tend to be over 20-fold increased in cohort analyses that use population-based comparisons of all leukemia risk, over 50-fold increased with population-based estimates of AML risk, and less in case-control analyses in which the reference group usually consisted of patients treated with radiotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7,9,12,26-28,32,34\">",
"     7,9,12,26-28,32,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of certain chemotherapy agents (eg, alkylating agents) is known to be associated with an increased risk of developing AML. The leukemia risk appears to be most related to total dose of alkylating agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) or nitrosoureas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/26-28,32,35\">",
"     26-28,32,35",
"    </a>",
"    ]. Anthracyclines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ) and epipodophyllotoxins (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/55/4983?source=see_link\">",
"     teniposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ), both of which are topoisomerase II inhibitors, may also increase the risk of leukemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis of acute myeloid leukemia\", section on 'Chemotherapy-induced AML'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The exact risk according to chemotherapy agent is difficult to estimate. This is largely due to the fact that patients receive combination chemotherapy and frequently receive more than one combination, especially if they are treated for relapse. This becomes a particular problem when combining several trials or series to have sufficient numbers of leukemias to permit analysis of risk factors.",
"   </p>",
"   <p>",
"    Exposure has usually been characterized as number of chemotherapy cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/26,27\">",
"     26,27",
"    </a>",
"    ] but the number of cycles does not take into consideration the individual doses of drugs, which can vary substantially according to individual toxicity. Despite this, a higher total dose of alkylating agents and nitrosoureas is the probable explanation for the higher leukemia rates noted after salvage or maintenance chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,27,32,36\">",
"     6,27,32,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk associated with specific alkylating agents and nitrosoureas varies; the risks appear highest after MOPP-treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,7,12,26,27,32\">",
"     6,7,12,26,27,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MOPP &mdash; The 15-year cumulative risk of AML after MOPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) has been estimated to be as high as 10 percent. More than six cycles of MOPP or MOPP-like regimens is associated with a very high risk of leukemia ranging from 20- to over 60-fold in comparison with patients treated with radiation alone and three- to fivefold compared with six or fewer cycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Mechlorethamine and procarbazine are usually given in combination, so that it is difficult to separate out their individual contributions to leukemogenesis. The risk of leukemia is unchanged among patients treated with variations of MOPP that substitute",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      for mechlorethamine, but may be reduced when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      is given in place of mechlorethamine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7,27-30\">",
"       7,27-30",
"      </a>",
"      ]. The lower risk associated with melphalan containing combinations may be due to the lower effective dose of melphalan given orally with variable absorption compared with mechlorethamine given intravenously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7\">",
"       7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The cumulative risk of leukemia following treatment with regimens that include procarbazine but not mechlorethamine appears lower than with MOPP-like regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/37\">",
"       37",
"      </a>",
"      ]. One study in which the cumulative doses of individual cytostatic drugs were available, and in which mechlorethamine and procarbazine dose were not highly correlated, showed that mechlorethamine rather than procarbazine had the strongest effect on leukemia risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ABVD &mdash; The 15-year cumulative risk of AML after ABVD (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ) has been estimated to be less than 1 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5,12,33,38\">",
"       5,12,33,38",
"      </a>",
"      ]. This is reflected in a decrease in leukemia risk among those treated for HL after 1980 when treatment with",
"      <span class=\"nowrap\">",
"       MOPP/ABVD",
"      </span>",
"      largely replaced MOPP-like combinations (2.1 versus 6.4 percent in one series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There is, however, also concern about the role of anthracyclines (eg, doxorubicin) and epipodophyllotoxins (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/55/4983?source=see_link\">",
"       teniposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ), both of which are topoisomerase II inhibitors, in the risk of leukemia. Limited evidence suggests that doxorubicin and epipodophyllotoxins in combination with higher doses of alkylating agents (including nitrosoureas) may have a synergistic effect in the risk of AML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/27,37,39\">",
"       27,37,39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link&amp;anchor=H13#H13\">",
"       \"Cytogenetics in acute myeloid leukemia\", section on 'Therapy-related myeloid neoplasms (t-MDS/t-AML)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      BEACOPP &mdash; The risk of developing AML within five years of treatment with escalated BEACOPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) is higher than that with standard BEACOPP or",
"      <span class=\"nowrap\">",
"       COPP/ABVD",
"      </span>",
"      (2.5 versus 0.6 and 0.4 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stanford V &mdash; AML does not appear to be increased among patients receiving the Stanford V regimen (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      plus radiation). No cases of",
"      <span class=\"nowrap\">",
"       AML/MDS",
"      </span>",
"      or non-Hodgkin lymphomas have occurred among a total of 256 patients treated in one series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have found a modest risk of acute leukemia, often not of statistical significance, associated with radiation therapy alone, in comparison to the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,7,12,22,31,42\">",
"     6,7,12,22,31,42",
"    </a>",
"    ]. There is suggestive evidence that the risk may be higher in patients receiving extensive radiotherapy (eg, total nodal irradiation or large fields including the pelvis), in which case a large amount of the bone marrow is in the treatment field and the radiation is being used more akin to a systemic agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8,26,30\">",
"     8,26,30",
"    </a>",
"    ]. In one report, for example, patients treated with radiation therapy alone, who received a total radiation dose to the bone marrow &gt;20 Gy, had a risk of leukemia that was eightfold higher than among those who received &lt;10 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis of acute myeloid leukemia\", section on 'Ionizing radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Chemotherapy plus radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting reports as to whether combined modality treatment does [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8,43-47\">",
"     8,43-47",
"    </a>",
"    ] or does not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,7,12,26-28,32\">",
"     6,7,12,26-28,32",
"    </a>",
"    ] produce greater risk of AML than chemotherapy alone. However, the preponderance of data do not support the notion that the combination of chemotherapy and radiotherapy, in particular, mantle irradiation, with or without upper abdominal irradiation, confers a higher risk of leukemia than chemotherapy alone. However, there is evidence that the use total nodal or large field and pelvic irradiation does increase the risk of leukemia seen in combination with alkylating agent chemotherapy. There is no evidence to suggest that the leukemia risk increases with increased radiation dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age over 35 to 40 years at treatment has been reported to be a significant risk factor for leukemia in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5,8,9,12,22\">",
"     5,8,9,12,22",
"    </a>",
"    ], but not in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7,28,29\">",
"     7,28,29",
"    </a>",
"    ]. The higher cumulative risk of AML in patients diagnosed over age 35 to 40 may simply reflect the higher baseline (general population) incidence of the disease in older persons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged thrombocytopenia has been associated with an increased risk of developing leukemia after chemotherapy for HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/27\">",
"     27",
"    </a>",
"    ]. Rather than reflecting a direct relationship, the thrombocytopenia in these patients may simply have been a marker of increased bioavailability of chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/27\">",
"     27",
"    </a>",
"    ]. Alternatively, there is considerable evidence that prolonged thrombocytopenia is a marker for permanent stem cell damage and that such patients have an increased risk for developing a leukemic clone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment and prognosis of therapy-associated AML is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NON-HODGKIN LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the relative risk (compared with the general population) of non-Hodgkin lymphoma (NHL) is increased among HL survivors, the absolute number of cases is low due to the low incidence in the general population. The reported incidence of NHL in large series of HL survivors has ranged from 0.9 percent at an average follow-up of 6.7 years (0.6 percent in the subset in continuous complete remission) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8,48\">",
"     8,48",
"    </a>",
"    ] to 1.6 percent at 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7\">",
"     7",
"    </a>",
"    ]. The relative risk for NHL progressively increased with follow-up time in most [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5,7,8,49\">",
"     5,7,8,49",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,29\">",
"     6,29",
"    </a>",
"    ]. Diffuse large B-cell lymphoma is the most common histology, accounting for 78 percent of the cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest experience comes from the International Database on Hodgkin's Disease, which evaluated the course of 12,411 patients with an average follow-up of 6.7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8\">",
"     8",
"    </a>",
"    ]. One hundred-six cases of NHL were observed with a continuous increase in relative risk with follow up in males (from 28.2 during the 5 to 9 year period, to 120 during the 15 to 19 year period). In females, the risk increase was confined to the first 15 years, with a peak relative risk of 45.4 during the 5 to 9 year observation period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little agreement on definitive risk factors for NHL in patients treated for HL. It is possible that differences among studies represent differences in the patient populations examined. It is also possible that pathologic misclassification may confound the results, with recurrent HL being misdiagnosed as NHL or NHL being initially misdiagnosed as HL. This issue is of lesser concern when modern histopathologic techniques are used. Only a few studies have included expert review of the original tissue diagnosis as part of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,12,48\">",
"     6,12,48",
"    </a>",
"    ]. The risk of NHL appears to have declined over the past decade, perhaps related to the use of less immunosuppressive chemotherapy regimens in the initial treatment of Hodgkin lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment modality",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data concerning the impact of initial treatment modality on the risk of subsequent NHL. Several studies have found no apparent differences in increased risk between patients treated with chemotherapy alone, radiotherapy alone, or a combination modality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,7,9,29\">",
"     6,7,9,29",
"    </a>",
"    ]. However, other reports suggested an increased risk with combined modality treatment and treatment for relapse. A large International Database study included 106 patients who developed NHL; combined modality treatment and any type of treatment for relapse were associated with increased risk for NHL with relative risks of 2.2 to 4.5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Host factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are also conflicting data on the importance of host factors such as gender and age on the risk for NHL. Some studies noted no relationship between these factors and NHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/50\">",
"     50",
"    </a>",
"    ], while the International Database and report from the Netherlands Cancer Institute found that increasing age over 30 and, to a lesser degree, male sex were risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8,12\">",
"     8,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Tumor factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of NHL may be related in part to the diagnosis of HL itself rather than its treatment. In particular, the histologic subtype of HL and the immunosuppressive effects of HL may influence the risk of NHL.",
"   </p>",
"   <p>",
"    The risk of developing NHL differs among patients with different HL histologies, with the greatest risk for NHL occurring in patients with nodular lymphocyte predominant disease (NLPHL) and the lowest risk in patients with nodular sclerosis (NSHL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8,12,50,51\">",
"     8,12,50,51",
"    </a>",
"    ]. In one study, for example, the relative risk of NHL among HL survivors compared with the general population was 55.6 with NLPHL compared with 9.8 with NSHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/50\">",
"     50",
"    </a>",
"    ]. In another report, NHL occurred in 22 of 3033 patients with HL randomized into clinical trials by the British National Lymphoma Investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/51\">",
"     51",
"    </a>",
"    ]. The frequency of NHL ranged from 3.8 percent in NLPHL to 0.3 percent in NSHL. It has been suggested that the transformation to NHL may be part of the natural history of NLPHL, rather than being related to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, HL may be associated with a general state of immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], which can predispose to the development of NHL as in transplant recipients. Support for this hypothesis comes from a detailed study of 14 patients who developed NHL within a median of 136 months from the diagnosis of HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/52\">",
"     52",
"    </a>",
"    ]. The high prevalence of extranodal sites, histology of either intermediate- or high-grade lymphomas, and immunophenotypic findings typical of NHL of B-cell lineage patients were similar to those of NHL arising in immunosuppressed patients. It has been our experienced that the incidence of NHL after HL has decreased, perhaps due to the reduction of disuse of myelosuppressive agent combinations such as MOPP. In addition, we are now seeing more indolent NHL after HL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data concerning the prognosis of NHL following the treatment of HL. Initial studies reported poor outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/53\">",
"     53",
"    </a>",
"    ]. However, later studies suggest that",
"    <strong>",
"     some",
"    </strong>",
"    of these patients may be curable with aggressive multiagent chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8,9,48,52\">",
"     8,9,48,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 106 patients with secondary NHL in the International Database on Hodgkin's Disease (diagnosed between 1960 and 1987), 45 were alive at the time of the report with a five-year probability of survival of 30 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective analysis of 52 patients who developed NHL after treatment for HL (diagnosed from 1981 to 1998) reported a two-year overall survival rate of 30 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective analysis of patients in the Surveillance, Epidemiology and End Results (SEER) program database treated from 2000 to 2004 reported five- and 10-year survival rates for patients with secondary NHL of 54 and 41 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SOLID CANCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid tumors account for approximately one-half to two-thirds of second malignancies developing after 15 or more years of follow-up in patients treated for HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5,6,9,12\">",
"     5,6,9,12",
"    </a>",
"    ]. The risk of solid tumor development depends greatly upon age at treatment, follow-up interval, and the type of treatment given.",
"   </p>",
"   <p>",
"    The excess risk of lung and breast cancers appears to be related to their proximity to the radiation portals. As an example, in one study of 202 patients surviving at least five years after treatment for HL, 20 of the 26 solid tumors following primary treatment were found within or adjoining the irradiated fields [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall relative risk for solid cancer, compared with general population expectations, is approximately 1.5 to 4.5 in long-term follow-up of studies of predominantly adults (",
"      <a class=\"graphic graphic_table graphicRef57099 \" href=\"mobipreview.htm?1/22/1391\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7-9,12,19,30,55-57\">",
"       7-9,12,19,30,55-57",
"      </a>",
"      ] but much larger (approximately 12) in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/32,58\">",
"       32,58",
"      </a>",
"      ]. There is a small increase in risk in the first five years, but this risk continues to increase out to at least 20 to 30 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7-10,12,32\">",
"       7-10,12,32",
"      </a>",
"      ], and perhaps indefinitely [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/19\">",
"       19",
"      </a>",
"      ]. The risk is inversely related to age at initial treatment. In one study, compared with the general population, patients who were first treated at age 31 to 39, 21 to 30, and 20 years of age or less, had a solid tumor relative risk of 4.9, 6.9, and 12.7, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cumulative risk of solid cancer in adults is approximately 9 to 13 percent at 15 to 20 years (",
"      <a class=\"graphic graphic_table graphicRef57099 \" href=\"mobipreview.htm?1/22/1391\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5-8,12,24,28,56,57,59\">",
"       5-8,12,24,28,56,57,59",
"      </a>",
"      ] and 18 to 26 percent at 30 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/19\">",
"       19",
"      </a>",
"      ]. In patients treated as children, the reported cumulative risk has been 4 percent at 15 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/32,58\">",
"       32,58",
"      </a>",
"      ] and 27 percent at 30 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/58,60\">",
"       58,60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of solid cancer overall is increased after radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5-7,28,30,32,61\">",
"     5-7,28,30,32,61",
"    </a>",
"    ]. Some studies have found an increased risk for solid cancers overall in patients treated with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,28,57,59,62,63\">",
"     6,28,57,59,62,63",
"    </a>",
"    ], while others have not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7,12,56,64\">",
"     7,12,56,64",
"    </a>",
"    ]. The data supporting the role of chemotherapy as a risk factor for secondary solid tumors are most compelling for non-Hodgkin lymphomas and lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Non-Hodgkin lymphoma'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Lung cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Large cohort studies of patients with HL have shown increased rates of a number of solid tumors including lung cancer, breast cancer, gastrointestinal cancer, melanoma and nonmelanoma skin cancers, bone and soft tissue cancers, and thyroid cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5-9,23,28,30,32,34,56,66-69\">",
"     5-9,23,28,30,32,34,56,66-69",
"    </a>",
"    ]. In the largest studies, an elevated risk of salivary gland cancer was also observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8,23\">",
"     8,23",
"    </a>",
"    ]. There have also been significantly increased risks in some studies for cancers of the mouth, tongue and pharynx, stomach, small intestine, colon, rectum, pancreas, pleura, cervix, ovary, and urogenital cancers overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6-9,12,23,28,30,32,34,56,58,69\">",
"     6-9,12,23,28,30,32,34,56,58,69",
"    </a>",
"    ] and, in children, for cancers of the esophagus and brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/32,34,58\">",
"     32,34,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung and breast cancer are the two most common solid malignancies in most large cohort studies with 15 or more years follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5-7,28\">",
"     5-7,28",
"    </a>",
"    ]. In the British National Lymphoma Investigation, for example, one-third of all excess malignancies were lung cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, an American study found that breast cancer was most common, with only 10 percent of excess second malignancies being lung cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/9\">",
"     9",
"    </a>",
"    ]. The relative risk of lung cancer is only slightly increased in the first five years after treatment, with larger relative risks (usually five or more) thereafter until at least 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5-8,23,28,56,70\">",
"     5-8,23,28,56,70",
"    </a>",
"    ]. The relative risk of lung cancer is highest in patients treated with both chemotherapy and radiation before age 25; after this age, the relative risk of second lung cancers decreases in patients treated with radiation but not with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/58,65,70\">",
"     58,65,70",
"    </a>",
"    ]. Lung cancers after chemotherapy occur earlier than those following radiation therapy.",
"   </p>",
"   <p>",
"    The prognosis of patients diagnosed with lung cancer following treatment of HL is worse than that of patients with de novo lung cancer. This was illustrated in a retrospective analysis that compared outcomes among the 187 of 22,648 HL survivors who developed non-small cell lung cancer (NSCLC) with those of 178,431 patients with de novo NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/71\">",
"     71",
"    </a>",
"    ]. When compared with patients with de novo NSCLC, HL survivors diagnosed with NSCLC had significantly inferior stage-specific overall survival rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of lung cancer is substantially increased in patients with HL treated with radiotherapy or chemotherapy, especially among those patients who smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,12,28,56,72\">",
"     6,12,28,56,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who have received radiation, most of the tumors are found within or adjoining the irradiated fields [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients who receive higher radiation doses appear to be at greater risk. One study, for example, found a strong dose-response relationship between radiation dose and the risk of lung cancer at that site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/72\">",
"     72",
"    </a>",
"    ]. There was a relative risk of 9.6 for a dose of &gt;9 Gy compared with &lt;1 Gy, with a possible downturn in risk for doses of 15 Gy or greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/72\">",
"     72",
"    </a>",
"    ]. The decrease in lung cancer risk at the highest doses has also been noted after radiotherapy for breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy appears to play a definite role in the development of second lung cancers following treatment of HL. In one mature series of second malignancies occurring after treatment in 5519 British patients with HL, lung cancer risk was significantly increased after chemotherapy (relative risk (RR) 3.3), radiotherapy (RR 2.9), and mixed modality treatment (RR 4.3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/65\">",
"     65",
"    </a>",
"    ]. Most other studies have found an increased risk of lung cancer with chemotherapy treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,28,30,70,74\">",
"     6,28,30,70,74",
"    </a>",
"    ], but some have not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/12,56,72\">",
"     12,56,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are conflicting data on whether certain regimens, such as those including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    and or multiple alkylating agents, are more likely to increase the risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,72\">",
"     6,72",
"    </a>",
"    ]. As an example, in two reports, the risk of lung cancer was significantly greater in those receiving MOPP chemotherapy as compared with those not receiving MOPP; further, the risk increased with the number of cycles of MOPP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In one of these studies, the risk of lung cancer was not increased following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (ChlVPP), implicating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    rather than procarbazine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/75\">",
"     75",
"    </a>",
"    ]. In the other, both mechlorethamine and procarbazine were implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smoking appears to considerably increase the risk of lung cancer after chest radiotherapy (relative risk of 13 for ever-smokers compared with never-smokers in one series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/74\">",
"     74",
"    </a>",
"    ]. The risk seems to be significantly increased in relation to the amount smoked after the diagnosis of HL (but not the amount smoked before diagnosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/72\">",
"     72",
"    </a>",
"    ]. There appears to be a more than a multiplicative relation between smoking-related and radiation-related risks (ie, the relative risk for smoking plus radiotherapy was greater than would be obtained by multiplying the separate relative risks for these exposures). Similar findings were noted in a case-control study in which the risk of lung cancer after treatment with both alkylating agents and radiotherapy was additive, while the risk of smoking was multiplicative (",
"    <a class=\"graphic graphic_table graphicRef78440 \" href=\"mobipreview.htm?14/59/15292\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that low-dose computed tomography scanning for patients at high risk for lung cancer allows for the discovery of a higher percentage of early stage disease, although the role of screening still remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Screening recommendations are presented in more detail separately. In one single institution retrospective study, long-term survival in patients who developed lung cancer after HL was only seen when the second cancer was identified as an incidental finding, providing additional evidence to support screening in high risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672644#H1167672644\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Follow-up for long-term complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative risk of breast cancer in women treated for HL has been only slightly increased to approximately 1.5 in most studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6-8,12,23,28,30,56\">",
"     6-8,12,23,28,30,56",
"    </a>",
"    ], but higher values have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/9,80-82\">",
"     9,80-82",
"    </a>",
"    ]. The absolute excess risks for all ages is not large; approximately one to two per 10,000 HL patients per year in most series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,12,28\">",
"     6,12,28",
"    </a>",
"    ] with a higher value (13 per 10,000 per year) being described in a later United States study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, among women treated before the age of 30 and followed for long durations, breast cancer is one of the most serious long-term sequelae of radiotherapy for HL. The raised risk of breast cancer occurs late, typically 10 or more years after first treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/12,80,81\">",
"     12,80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three major risk factors for breast cancer are the age at treatment for HL, the use (and amount) of mantle radiotherapy, and the effect of alkylating and other agents on ovarian function (",
"    <a class=\"graphic graphic_table graphicRef78361 \" href=\"mobipreview.htm?22/5/22620\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age at treatment &mdash; The risk of breast cancer is inversely related to age at treatment. Among females treated before the age of 16, the relative risk of breast cancer has ranged from 17 to 458 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5,9,32,34,81,85,86\">",
"       5,9,32,34,81,85,86",
"      </a>",
"      ]. There is a similar variability in the actuarial risk of developing breast cancer among females under age 20, ranging from 12 percent to as high as 42 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/34,58,60,87\">",
"       34,58,60,87",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The risk declines steeply with age at treatment. In one study, for example, the actuarial risk for developing breast cancer 25 years after therapy was 34, 22, and 3.5 percent for women who received radiation therapy at age &lt;20, 20 to 29, and &ge;30, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/87\">",
"       87",
"      </a>",
"      ]. In general, there is little if any increase in relative risk in women treated at age 30 or later [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5,9,28,81,85,87,88\">",
"       5,9,28,81,85,87,88",
"      </a>",
"      ]. This inverse relation to age suggests that the breast epithelium is sensitive to the carcinogenic effect of radiation during a \"window\" of risk before its terminal differentiation.",
"     </li>",
"     <li>",
"      Mantle radiotherapy &mdash; The main cause of the large risk of breast cancer after HL is mantle radiotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/89\">",
"       89",
"      </a>",
"      ]. Almost all cases have been in or at the margin of the radiation field. In three studies with a total of 59 cases, for example, breast cancer was in the field or at the margin in 54 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/32,34,81\">",
"       32,34,81",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The importance of radiotherapy and the role of dose were evaluated in a large matched case-control study of 3817 young women with HL diagnosed at &le;30 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/90\">",
"       90",
"      </a>",
"      ]. A radiation dose of &ge;4 Gy delivered to the breast was associated with a 3.2-fold increased risk of breast cancer (95% CI: 1.4-8.2), as compared with the risk in patients who received both &lt;4 Gy and no alkylating agents. The risk increased to eightfold with a dose of &gt;40 Gy. A separately published subgroup analysis came to similar conclusions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other factors &mdash; Other factors that might alter the risk of developing breast cancer in HL include the effect of MOPP chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/81,87\">",
"       81,87",
"      </a>",
"      ], splenectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/92\">",
"       92",
"      </a>",
"      ], and splenic irradiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/32,55\">",
"       32,55",
"      </a>",
"      ]. However, the importance of these factors is not well established and, to the degree that it induces premature menopause, MOPP might actually be protective. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=see_link\">",
"       \"Factors that modify breast cancer risk in women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A large nested case-control study, and a separately published subgroup analysis, evaluated the effect of several factors other than radiotherapy (RT) in patients developing breast cancer after the diagnosis of HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Treatment with both chemotherapy (MOPP or MOPP-like) and RT was associated with a significantly lower risk of developing breast cancer than treatment with RT alone (relative risk 0.45, 95% CI: 0.22-0.91). Premature menopause following chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pelvic (ovarian) radiation also resulted in a lessened risk. Taken together, these results suggest that hormonal stimulation may promote tumorigenesis in patients with HL after RT has produced an initiating event. These results also suggest that treatment with preventative agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    might provide a strategy to reduce breast cancer incidence in high risk patients.",
"   </p>",
"   <p>",
"    There are few data available on the effects of reproductive history, hormone supplementation, family history of breast cancer, or genotype on the radiotherapy-related risks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/93\">",
"     93",
"    </a>",
"    ]. However, one retrospective study investigated the potential contribution of pregnancy to the late development of breast cancer in 382 women with HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/94\">",
"     94",
"    </a>",
"    ]. Women receiving RT during pregnancy or within one month of pregnancy had an increased incidence of breast cancer compared with nonpregnant women and women receiving RT later than one month after completion of pregnancy (hazard ratio 22, 95 percent confidence interval: 6 to 91).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Clinical and pathologic characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several retrospective studies have described the clinical and pathologic features of patients who developed breast cancer after treatment for HL. Patients with second cancers appear to be younger with a higher incidence of bilateral disease than women with primary breast cancer. The median age at diagnosis is 30 to 40 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/66,85,95\">",
"     66,85,95",
"    </a>",
"    ], while 20 to 25 percent have bilateral disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breast cancer that develops after treatment for HL may display more aggressive pathologic characteristics when compared with sporadic cases of breast cancer. There have been several small hospital-based case-control and case-series evaluating the pathologic features of breast cancer in HL survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/95-100\">",
"     95-100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest study was an analysis of the Surveillance, Epidemiology, and End Results (SEER) database which included 2645 female patients who were diagnosed with HL before age 35, treated with radiation therapy as part of their initial therapy between 1973 and 2000, and survived at least five years from initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/101\">",
"     101",
"    </a>",
"    ]. When compared with the general population, these patients had a sixfold increased risk of developing invasive breast cancer. The majority was ductal adenocarcinoma (79 percent) and developed in the upper outer quadrant of the breast. When compared with sporadic breast cancers, these tumors were more likely to display features associated with poor outcome such as estrogen and progesterone receptor negativity and high grade. Other studies have not seen these differences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients who develop breast cancer after treatment of HL is variable, but appears to be worse overall than that of patients who develop breast cancer de novo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/102\">",
"     102",
"    </a>",
"    ]. However, because of the heightened awareness of the breast cancer risk, some studies have shown that these tumors are picked up at an early stage, and have a good prognosis despite the presence of poor prognostic features. The prognosis is dependent upon nodal status at presentations, as in patients with primary breast cancer. As an example, an ongoing study at Harvard Medical School evaluating MRI versus mammography has detected 16 breast cancers; only one patient had node positive disease suggesting a relatively good prognosis for patients who develop breast cancer that is detected by careful surveillance after treatment of Hodgkin lymphoma.",
"   </p>",
"   <p>",
"    In one series, for example, the five-year disease-free survival rates were much higher for patients with node-negative tumors compared with those with axillary involvement (85 versus 33 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/95\">",
"     95",
"    </a>",
"    ]. In another report, the five-year disease-specific survival rate for pN0, pN1-3, and pN greater than 3, were 91, 66, and zero percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/96\">",
"     96",
"    </a>",
"    ]. In addition, the tumor aggressiveness appears to vary. &nbsp;(See",
"    <a class=\"local\" href=\"#H27\">",
"     'Clinical and pathologic characteristics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The majority of women who develop breast cancer and require local therapy to the breast are treated with mastectomy because of the risk of tissue necrosis after repeat irradiation of the breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/80\">",
"     80",
"    </a>",
"    ]. With the use of partial breast irradiation with brachytherapy or conformal external beam irradiation it may be possible to use lumpectomy and radiation therapy for patients with limited stage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/103\">",
"     103",
"    </a>",
"    ]. However, this approach should be offered as part of a clinical investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vigorous patient education program coupled with an early detection program for female patients treated with mantle irradiation might lead to earlier detection and improved survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/80,104-107\">",
"     80,104-107",
"    </a>",
"    ]. The best screening program has yet to be defined and clinical practice varies. Given the paucity of data supporting one screening program over another, we believe that patients should be encouraged to participate in ongoing clinical trials investigating the use of MRI, in addition to screening mammograms in this high risk population.",
"   </p>",
"   <p>",
"    Small prospective trials and retrospective analyses have demonstrated that screening programs can detect breast cancers in this population at an early stage. As an example, a prospective study of 90 female long-term survivors of Hodgkin lymphoma, all of whom had been treated with mantle irradiation, included patient questionnaires concerning awareness of the increased risk for breast cancer, written recommendations for breast examination and mammography, and annual follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/108\">",
"     108",
"    </a>",
"    ]. Ten women developed 12 breast cancers during the study. All were evident on mammography; 8 of the 10 invasive cancers were node negative.",
"   </p>",
"   <p>",
"    A retrospective study evaluated the use of screening breast MRI in 91 women with a history of chest irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/109\">",
"     109",
"    </a>",
"    ]. The median age at the time of primary cancer diagnosis and presumed age at mediastinal radiation was 24 years. A total of 247 screening MRI examinations were performed over nine years. Suspicious lesions were detected on 27 MRI images (11 percent) among 21 patients, 30 of which were biopsied. Ten breast cancers were diagnosed; of these, four were detected by MRI alone, three were identifiable on MRI and mammography, while three were detected with mammography alone. These results suggest that MRI may provide additional information to that obtained by mammography, but cannot be used in place of screening mammography in this population.",
"   </p>",
"   <p>",
"    Another ongoing prospective trial at Harvard Medical School using both screening mammography and MRI detected 16 breast cancers. MRI detected five breast cancers that were missed by mammography, while mammography detected six breast cancers missed by MRI. MRI was associated with a higher false positive rate and led to more negative biopsies than mammography",
"   </p>",
"   <p>",
"    Outside of a clinical trial, our practice is to perform annual mammography in women treated with mantle irradiation starting 8 to 10 years after treatment or at age 40, whichever is first [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/110\">",
"     110",
"    </a>",
"    ]. The American Cancer Society has recommended magnetic resonance imaging (MRI) screening in Hodgkin lymphoma survivors at high risk for breast cancer, such as those who received radiation to the chest between the ages of 10 and 35 years, although there are no data supporting this recommendation (",
"    <a class=\"graphic graphic_table graphicRef78361 \" href=\"mobipreview.htm?22/5/22620\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. The combination of mammography plus ultrasound may be an acceptable, less costly, alternative in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/113\">",
"     113",
"    </a>",
"    ]. Either of these more intensive screening methods would be expected to increase the rate of false positives. The role of chemoprevention with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    is yet undefined in this patient group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672644#H1167672644\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Follow-up for long-term complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Bone and soft tissue cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone and soft tissue cancers, including nonepithelial malignancies of the breast, are rare. Thus, although patients treated for HL have a large relative risk of developing these lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7,8,23,28\">",
"     7,8,23,28",
"    </a>",
"    ], they account for only 5 to 10 percent of the absolute excess risk of second malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,7,9\">",
"     6,7,9",
"    </a>",
"    ]. There are too few cases in most studies to assess variation in risk over time. In children treated for cancer generally, relative risks of bone cancer continue to rise from 2 to 4, to over 20 years after first treatment, with a relative risk of several hundred at 20 and more years follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/3/28729?source=see_link\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone and soft tissue tumor risks are greatly increased after radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/30,114\">",
"     30,114",
"    </a>",
"    ]. As an example, a study in childhood cancer survivors found that the risk of bone sarcoma rose sharply with increasing radiation dose above 10 Gy, reaching a 40-fold excess at doses of 60 Gy or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some evidence that chemotherapy also may play a role in the development of bone and soft tissue tumors after HL. One large study found a sixfold relative risk in relation to chemotherapy, with significant risks at zero to 4, 5 to 9, and 10 and more years after first treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/30\">",
"     30",
"    </a>",
"    ]. The increase in risk was associated with the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    . In addition, bone sarcomas have been associated with alkylating agent administration in childhood cancer survivors in general [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Thyroid cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid cancers are uncommon after treatment of HL. The absolute excess risk is about 1 to 3 per 10,000 patients per year, representing approximately 2 percent of the excess risk of second cancers overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6,28,68\">",
"     6,28,68",
"    </a>",
"    ]. The risk is much greater after treatment in childhood with a relative risk of 33 to 67 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/32,34,66\">",
"     32,34,66",
"    </a>",
"    ]. Among patients under age 20, a relative risk as high as 790 has been described in children treated between the ages of zero and four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/34\">",
"     34",
"    </a>",
"    ]. The risk of thyroid cancer appears to be increased throughout follow-up to 20 and more years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/23,32\">",
"     23,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiotherapy is the main cause of thyroid cancers after HL, since the thyroid is a highly radiosensitive organ, particularly in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/66,115\">",
"     66,115",
"    </a>",
"    ]. A possible link to chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    and other alkylating agents has also been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small series have shown that thyroid cancers following radiotherapy for HL usually develop within the radiation field [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/34,68\">",
"     34,68",
"    </a>",
"    ]. This is compatible with the experience with thyroid cancer after childhood radiation exposure in other circumstances; 68 percent arose within the radiation field [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/66\">",
"     66",
"    </a>",
"    ]. The risk increases with radiation dose up to 10 Gy and then appears to level off or even decrease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/66,115\">",
"     66,115",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1818?source=see_link\">",
"     \"Radiation-induced thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Malignant melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative risk of malignant melanoma after treatment of HL is approximately two and appears to be the same in patients treated in childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/32,34\">",
"     32,34",
"    </a>",
"    ] or as adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5,7-9,23,28,30,56\">",
"     5,7-9,23,28,30,56",
"    </a>",
"    ]. The absolute excess rate is 2 to 4 per 10,000 HL patients per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5,7,9,28\">",
"     5,7,9,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study that evaluated the time course of this risk in six patients, most lesions occurred in the first five years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/67\">",
"     67",
"    </a>",
"    ]. Two of the patients had more than one primary melanoma, and five had biopsy or clinical evidence of dysplastic nevus syndrome, suggesting that patients with this syndrome may be at increased risk.",
"   </p>",
"   <p>",
"    The factors responsible for the apparent increase in melanoma risk in these patients are uncertain. There has been some evidence of increased risk in association with radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/30\">",
"     30",
"    </a>",
"    ] but this is not a relation that would be expected from the radiation literature generally. It is possible that the melanoma risk is due to immunosuppression rather than a carcinogenic effect of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Gastrointestinal cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal (GI) cancers account for about 10 percent of the excess risk of cancer after HL; the relative risk is about 2.5 with an absolute excess risk of about 6 per 10,000 HL patients per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5,69\">",
"     5,69",
"    </a>",
"    ]. The risk first increases at five years after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5,8\">",
"     5,8",
"    </a>",
"    ] and may continue to rise through 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/69,80\">",
"     69,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Much greater risks of esophageal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/34\">",
"     34",
"    </a>",
"    ], colorectal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/32,34\">",
"     32,34",
"    </a>",
"    ], and gastric cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/9,32\">",
"     9,32",
"    </a>",
"    ] occur in patients treated under age 20. The relative risk of gastrointestinal cancer falls with increasing age at first treatment in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type of therapy for HL appears to influence the risk of developing secondary GI cancer. In one study of 5519 British patients with HL, the risk of developing secondary GI cancers was highest after combined modality therapy (RR = 3.3), lower after radiotherapy alone (RR = 1.7), and nonsignificantly increased following chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/65\">",
"     65",
"    </a>",
"    ]. Others report similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/69,116\">",
"     69,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis of HL survivors who develop GI cancers appears to be worse than that of patients with an initial primary GI cancer. A retrospective study of the Surveillance, Epidemiology, and End Results (SEER) database compared the survival of 209 HL survivors with secondary GI cancer (105 colon, 35 stomach, 30 pancreas, 21 rectum, and 18 esophagus) to that of 484,165 patients with first primary GI cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/117\">",
"     117",
"    </a>",
"    ]. While outcomes following localized stage colon cancer were similar to those with primary disease, HL survivors who developed advanced stage colon cancer or stomach cancer had significantly worse survival than those with primary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Mesothelioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HL appear to be at an increased risk for developing malignant mesothelioma. This was best demonstrated in a cohort study of 2567 patients from the Netherlands who survived at least five years after treatment for HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/118\">",
"     118",
"    </a>",
"    ]. After a median follow-up of 18.1 years, malignant mesothelioma had been diagnosed in eight men and five women with a median time from treatment of HL to diagnosis of mesothelioma of 27.7 years. When compared with the general population, there was an almost 26-fold increased risk for mesothelioma among patients treated for HL (standardized incidence ratio of 25.7) resulting in an absolute excess of 3.5 cases of mesothelioma per 10,000 patients per year. In an exploratory analysis, factors that appeared to increase this risk included female gender, first treatment at age less than 31 years, and the incorporation of radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Other solid cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is relatively little evidence concerning the risk of other solid cancers among patients treated for Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/26/35242/abstract/30\">",
"     30",
"    </a>",
"    ]. On the basis of radiation epidemiology, it is likely that the risk of salivary gland tumors, nonmelanoma skin cancers, and bladder cancer may be increased after radiotherapy for HL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients with Hodgkin lymphoma (HL) are able to achieve long-term survival free of HL with modern therapy. With this success, late complications of treatment have emerged as a competing cause of death and morbidity among these patients. Long-term survivors are at risk for developing second malignancies, cardiovascular disease, pulmonary disease, thyroid dysfunction, sterility, and other complications. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Relative and absolute risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Solid tumors account for the majority of second cancers in HL survivors with breast, lung, and colon cancer being the most frequent. Leukemia and non-Hodgkin lymphoma (NHL) are less common, but occur much more frequently in this population when compared with the general population. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Solid cancers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute leukemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Non-Hodgkin lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that affect the risk of developing a second malignancy in this population include (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Effect of treatment given'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Radiation dose and fields",
"     </li>",
"     <li>",
"      Chemotherapy agents and doses administered",
"     </li>",
"     <li>",
"      Patient age at treatment",
"     </li>",
"     <li>",
"      Smoking history",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening studies for second cancers in this population are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672644#H1167672644\">",
"       \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Follow-up for long-term complications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/1\">",
"      Bonadonna G, De Lena M, Banfi A, Lattuada A. Secondary neoplasms in malignant lymphomas after intensive therapy. N Engl J Med 1973; 288:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/2\">",
"      Canellos GP, Arseneau JC, DeVita VT, et al. Second malignancies complicating Hodgkin's disease in remission. Lancet 1975; 1:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/3\">",
"      Arseneau JC, Sponzo RW, Levin DL, et al. Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med 1972; 287:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/4\">",
"      Best T, Li D, Skol AD, et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 2011; 17:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/5\">",
"      van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/6\">",
"      Swerdlow AJ, Douglas AJ, Hudson GV, et al. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 1992; 304:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/7\">",
"      Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/8\">",
"      Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 1992; 3 Suppl 4:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/9\">",
"      Mauch PM, Kalish LA, Marcus KC, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 1996; 87:3625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/10\">",
"      Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/11\">",
"      Constine LS, Tarbell N, Hudson MM, et al. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys 2008; 72:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/12\">",
"      van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/13\">",
"      Nyandoto P, Muhonen T, Joensuu H. Second cancer among long-term survivors from Hodgkin's disease. Int J Radiat Oncol Biol Phys 1998; 42:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/14\">",
"      Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/15\">",
"      Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997; 8 Suppl 1:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/16\">",
"      Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20:3484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/17\">",
"      Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21:3431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/18\">",
"      Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011; 29:4096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/19\">",
"      Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007; 25:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/20\">",
"      Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006; 17:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/21\">",
"      Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1995; 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/22\">",
"      Schonfeld SJ, Gilbert ES, Dores GM, et al. Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients. J Natl Cancer Inst 2006; 98:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/23\">",
"      Kaldor JM, Day NE, Band P, et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer 1987; 39:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/24\">",
"      Cimino G, Papa G, Tura S, et al. Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. J Clin Oncol 1991; 9:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/25\">",
"      Tura S, Fiacchini M, Zinzani PL, et al. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. J Clin Oncol 1993; 11:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/26\">",
"      Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/27\">",
"      van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994; 12:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/28\">",
"      Swerdlow AJ, Barber JA, Horwich A, et al. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. Br J Cancer 1997; 75:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/29\">",
"      Abrahamsen JF, Andersen A, Hannisdal E, et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 1993; 11:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/30\">",
"      Boivin JF, Hutchison GB, Zauber AG, et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995; 87:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/31\">",
"      Henry-Amar M, Dietrich PY. Acute leukemia after the treatment of Hodgkin's disease. Hematol Oncol Clin North Am 1993; 7:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/32\">",
"      Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/33\">",
"      Delwail V, Jais JP, Colonna P, Andrieu JM. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol 2002; 118:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/34\">",
"      Sankila R, Garwicz S, Olsen JH, et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 1996; 14:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/35\">",
"      Koontz MZ, Horning SJ, Balise R, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol 2013; 31:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/36\">",
"      Devereux S, Selassie TG, Vaughan Hudson G, et al. Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. BMJ 1990; 301:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/37\">",
"      Schellong G, Riepenhausen M, Creutzig U, et al. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group. J Clin Oncol 1997; 15:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/38\">",
"      Canellos GP. Can MOPP be replaced in the treatment of advanced Hodgkin's disease? Semin Oncol 1990; 17:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/39\">",
"      Sandoval C, Pui CH, Bowman LC, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 1993; 11:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/40\">",
"      Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/41\">",
"      Horning SJ, Hoppe RT, Advani R, et al. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: Mature data in early and advanced stage patients (abstract). Blood 2004; 104:92a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/42\">",
"      Boivin JF, Hutchison GB, Lyden M, et al. Second primary cancers following treatment of Hodgkin's disease. J Natl Cancer Inst 1984; 72:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/43\">",
"      Tester WJ, Kinsella TJ, Waller B, et al. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol 1984; 2:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/44\">",
"      Mauch PM, Canellos GP, Rosenthal DS, Hellman S. Reduction of fatal complications from combined modality therapy in Hodgkin's disease. J Clin Oncol 1985; 3:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/45\">",
"      Andrieu JM, Ifrah N, Payen C, et al. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1990; 8:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/46\">",
"      Brusamolino E, Anselmo AP, Klersy C, et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica 1998; 83:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/47\">",
"      S&eacute;n&eacute;cal D, Jais JP, Desablens B, et al. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation. Cancer 2008; 112:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/48\">",
"      Rueffer U, Josting A, Franklin J, et al. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis. J Clin Oncol 2001; 19:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/49\">",
"      Enrici RM, Anselmo AP, Iacari V, et al. The risk of non-Hodgkin's lymphoma after Hodgkin's disease, with special reference to splenic treatment. Haematologica 1998; 83:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/50\">",
"      Swerdlow AJ, Douglas AJ, Vaughan Hudson G, et al. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. Br J Cancer 1993; 68:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/51\">",
"      Bennett MH, MacLennan KA, Vaughan Hudson G, Vaughan Hudson B. Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. British National Lymphoma Investigation. Ann Oncol 1991; 2 Suppl 2:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/52\">",
"      Zarate-Osorno A, Medeiros LJ, Longo DL, Jaffe ES. Non-Hodgkin's lymphomas arising in patients successfully treated for Hodgkin's disease. A clinical, histologic, and immunophenotypic study of 14 cases. Am J Surg Pathol 1992; 16:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/53\">",
"      Jacquillat C, Khayat D, Desprez-Curely JP, et al. Non-Hodgkin's lymphoma occurring after Hodgkin's disease. Four new cases and a review of the literature. Cancer 1984; 53:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/54\">",
"      Pulte D, Gondos A, Brenner H. Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy. Leuk Lymphoma 2009; 50:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/55\">",
"      Dietrich PY, Henry-Amar M, Cosset JM, et al. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? Blood 1994; 84:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/56\">",
"      Foss Abrahamsen A, Andersen A, Nome O, et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol 2002; 13:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/57\">",
"      Rodriguez MA, Fuller LM, Zimmerman SO, et al. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol 1993; 4:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/58\">",
"      Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011; 117:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/59\">",
"      Biti G, Cellai E, Magrini SM, et al. Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 1994; 29:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/60\">",
"      Bhatia S, Robison LL, Oberlin O. Late effects of treatment for childhood Hodgkin's disease (letter). N Engl J Med 1996; 335:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/61\">",
"      Barbaro PM, Johnston K, Dalla-Pozza L, et al. Reduced incidence of second solid tumors in survivors of childhood Hodgkin's lymphoma treated without radiation therapy. Ann Oncol 2011; 22:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/62\">",
"      Tarbell NJ, Gelber RD, Weinstein HJ, Mauch P. Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood. Lancet 1993; 341:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/63\">",
"      Andr&eacute; M, Henry-Amar M, Blaise D, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998; 92:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/64\">",
"      Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/65\">",
"      Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000; 18:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/66\">",
"      Tucker MA, Jones PH, Boice JD Jr, et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res 1991; 51:2885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/67\">",
"      Tucker MA, Misfeldt D, Coleman CN, et al. Cutaneous malignant melanoma after Hodgkin's disease. Ann Intern Med 1985; 102:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/68\">",
"      Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 1991; 325:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/69\">",
"      Birdwell SH, Hancock SL, Varghese A, et al. Gastrointestinal cancer after treatment of Hodgkin's disease. Int J Radiat Oncol Biol Phys 1997; 37:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/70\">",
"      Ibrahim EM, Kazkaz GA, Abouelkhair KM, et al. Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis. Lung 2013; 191:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/71\">",
"      Milano MT, Li H, Constine LS, Travis LB. Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients. Cancer 2011; 117:5538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/72\">",
"      van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995; 87:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/73\">",
"      Inskip PD, Stovall M, Flannery JT. Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 1994; 86:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/74\">",
"      Kaldor JM, Day NE, Bell J, et al. Lung cancer following Hodgkin's disease: a case-control study. Int J Cancer 1992; 52:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/75\">",
"      Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001; 19:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/76\">",
"      Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/77\">",
"      Black WC, Baron JA. CT screening for lung cancer: spiraling into confusion? JAMA 2007; 297:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/78\">",
"      International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/79\">",
"      Schoenfeld JD, Mauch PM, Das P, et al. Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome. Ann Oncol 2012; 23:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/80\">",
"      Wolden SL, Hancock SL, Carlson RW, et al. Management of breast cancer after Hodgkin's disease. J Clin Oncol 2000; 18:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/81\">",
"      Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993; 85:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/82\">",
"      De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009; 27:4239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/83\">",
"      Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/84\">",
"      Swerdlow AJ, Cooke R, Bates A, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. J Clin Oncol 2012; 30:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/85\">",
"      Travis LB, Curtis RE, Boice JD Jr. Late effects of treatment for childhood Hodgkin's disease. N Engl J Med 1996; 335:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/86\">",
"      Guibout C, Adjadj E, Rubino C, et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol 2005; 23:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/87\">",
"      Aisenberg AC, Finkelstein DM, Doppke KP, et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 1997; 79:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/88\">",
"      Alm El-Din MA, Hughes KS, Finkelstein DM, et al. Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter. Int J Radiat Oncol Biol Phys 2009; 73:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/89\">",
"      Basu SK, Schwartz C, Fisher SG, et al. Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys 2008; 72:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/90\">",
"      Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003; 290:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/91\">",
"      van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003; 95:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/92\">",
"      Wahner-Roedler DL, Nelson DF, Croghan IT, et al. Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience. Mayo Clin Proc 2003; 78:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/93\">",
"      Ma YP, van Leeuwen FE, Cooke R, et al. FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma. Blood 2012; 119:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/94\">",
"      Chen J, Lee RJ, Tsodikov A, et al. Does radiotherapy around the time of pregnancy for Hodgkin's disease modify the risk of breast cancer? Int J Radiat Oncol Biol Phys 2004; 58:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/95\">",
"      Yahalom J, Petrek JA, Biddinger PW, et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 1992; 10:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/96\">",
"      Cutuli B, Dhermain F, Borel C, et al. Breast cancer in patients treated for Hodgkin's disease: clinical and pathological analysis of 76 cases in 63 patients. Eur J Cancer 1997; 33:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/97\">",
"      Castiglioni F, Terenziani M, Carcangiu ML, et al. Radiation effects on development of HER2-positive breast carcinomas. Clin Cancer Res 2007; 13:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/98\">",
"      Gaffney DK, Hemmersmeier J, Holden J, et al. Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2. Int J Radiat Oncol Biol Phys 2001; 49:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/99\">",
"      Janov AJ, Tulecke M, O'Neill A, et al. Clinical and pathologic features of breast cancers in women treated for Hodgkin's disease: a case-control study. Breast J 2001; 7:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/100\">",
"      Sanna G, Lorizzo K, Rotmensz N, et al. Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors. Ann Oncol 2007; 18:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/101\">",
"      Dores GM, Anderson WF, Beane Freeman LE, et al. Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy. Br J Cancer 2010; 103:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/102\">",
"      Milano MT, Li H, Gail MH, et al. Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. J Clin Oncol 2010; 28:5088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/103\">",
"      Haberer S, Belin L, Le Scodan R, et al. Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option. Int J Radiat Oncol Biol Phys 2012; 82:e145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/104\">",
"      Kash KM, Dabney MK. Psychological aspects of cancer screening in high-risk populations. Med Pediatr Oncol 2001; 36:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/105\">",
"      Dershaw DD, Yahalom J, Petrek JA. Breast carcinoma in women previously treated for Hodgkin disease: mammographic evaluation. Radiology 1992; 184:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/106\">",
"      Dershaw DD. Mammographic screening of the high-risk woman. Am J Surg 2000; 180:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/107\">",
"      Deniz K, O'Mahony S, Ross G, Purushotham A. Breast cancer in women after treatment for Hodgkin's disease. Lancet Oncol 2003; 4:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/108\">",
"      Diller L, Medeiros Nancarrow C, Shaffer K, et al. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol 2002; 20:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/109\">",
"      Sung JS, Lee CH, Morris EA, et al. Screening breast MR imaging in women with a history of chest irradiation. Radiology 2011; 259:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/110\">",
"      Bloom JR, Stewart SL, Hancock SL. Breast cancer screening in women surviving Hodgkin disease. Am J Clin Oncol 2006; 29:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/111\">",
"      Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/112\">",
"      Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/113\">",
"      Alm El-Din MA, El-Badawy SA, Taghian AG. Breast cancer after treatment of Hodgkin's lymphoma: general review. Int J Radiat Oncol Biol Phys 2008; 72:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/114\">",
"      Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/115\">",
"      Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995; 141:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/116\">",
"      van den Belt-Dusebout AW, Aleman BM, Besseling G, et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 2009; 75:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/117\">",
"      Youn P, Li H, Milano MT, et al. Long-term survival among Hodgkin's lymphoma patients with gastrointestinal cancer: a population-based study. Ann Oncol 2013; 24:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/26/35242/abstract/118\">",
"      De Bruin ML, Burgers JA, Baas P, et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood 2009; 113:3679.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4764 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-06743D8BDE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35242=[""].join("\n");
var outline_f34_26_35242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL OBSERVATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Relative and absolute risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect of elapsed time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect of treatment given",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACUTE LEUKEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Chemotherapy plus radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NON-HODGKIN LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment modality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Host factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Tumor factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SOLID CANCERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Clinical and pathologic characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Bone and soft tissue cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Malignant melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Gastrointestinal cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Other solid cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4764\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4764|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/61/36829\" title=\"figure 1\">",
"      Mortality in Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4764|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/22/1391\" title=\"table 1\">",
"      Second CA after treatment HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/59/15292\" title=\"table 2\">",
"      Lung cancer risk Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/5/22620\" title=\"table 3\">",
"      Breast cancer risk Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=related_link\">",
"      Long-term follow-up of the patient with classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28280?source=related_link\">",
"      Malignancy after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=related_link\">",
"      Pathogenesis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1818?source=related_link\">",
"      Radiation-induced thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_26_35243="Diff dx hyperammonemia";
var content_f34_26_35243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of hyperammonemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Reye's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract infection with a urease-producing organism (eg Proteus mirabilis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ureterosigmoidostomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe muscle exertion/heavy exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cigarette smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient hyperammonemia in newborns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Certain inborn errors of metabolism (urea cycle defects and organic acidemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any cause of porto-systemic shunting of blood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parenteral nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        After high-dose chemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drugs such as:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Valproic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Barbiturates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Narcotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylate intoxication",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35243=[""].join("\n");
var outline_f34_26_35243=null;
var title_f34_26_35244="Molecular test brain lesion";
var content_f34_26_35244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Molecular tests for infectious causes of intracranial mass lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Availability*",
"       </td>",
"       <td class=\"subtitle1\">",
"        When inclusion of NAAT is indicated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preferred testing method(s)&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abscess&Delta;",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        Gram's stain positive, culture negative; prior antibacterial therapy",
"       </td>",
"       <td>",
"        Gram's stain, culture prior to antibacterial therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycobacterium tuberculosis&loz;",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Potentially",
"       </td>",
"       <td>",
"        AFB stain, culture, histologic exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein Barr virus (EBV), primary central nervous system lymphoma (PCNSL)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        NAAT, preferably quantitative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        JC virus, progressive multifocal leukoencephalopathy (PML)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        NAAT, preferably quantitative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Spirochetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treponema pallidum (syphilis)",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Serology, CSF VDRL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Fungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cryptococcus",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Antigen detection, culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"       <td>",
"        Culture, serology, histologic exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Parasites",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"       <td>",
"        Stains, Serology, histologic exam",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPV: positive predictive value; PCR: polymerase chain reaction; CDC: Centers for Disease Control and Prevention; NAAT: nucleic acid amplification testing; CSF: cerebrospinal fluid; AFB: acid fast bacilli.",
"     <br>",
"      * Widespread: readily available; Yes: consistently available, but not yet common; Limited: one or two specialized laboratories (eg, Centers for Disease Control and Prevention (CDC) or research groups).",
"      <br>",
"       &bull; Testing on brain mass tissue.",
"       <br>",
"        &Delta; 16s rDNA \"Universal\" PCR.",
"        <br>",
"         &loz; Limited experience, presumably poor sensitivity, high PPV.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35244=[""].join("\n");
var outline_f34_26_35244=null;
var title_f34_26_35245="Prognosis troponin T level";
var content_f34_26_35245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Positive serum troponin T predicts lower survival after myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 313px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier estimates of survival show that a positive serum troponin, obtained any time during the first 24 hours after admission for an acute coronary syndrome, predicts a higher mortality at 30 days and one year.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Newby LK, Christenson RH, Ohman M, et al. for the GUSTO IIa Investigators, Circulation 1998; 98:1853.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35245=[""].join("\n");
var outline_f34_26_35245=null;
var title_f34_26_35246="Hormones and menses";
var content_f34_26_35246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F72415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F72415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Hormonal changes during normal menstrual cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 211px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequential changes in the serum concentrations of the hormones released from the pituitary (FSH and LH; left panel) and from the ovaries (estrogen and progesterone; right panel) during the normal menstrual cycle. By convention, the first day of menses is day 1 of the cycle (shown here as day -14). The cycle is then divided into two phases: the follicular phase is from the onset of menses until the LH surge (day 0); and the luteal phase is from the peak of the LH surge until the next menses. To convert serum estradiol values to pmol/L, multiply by 3.67, and to convert serum progesterone values to nmol/L, multiply by 3.18.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35246=[""].join("\n");
var outline_f34_26_35246=null;
var title_f34_26_35247="Adenosine metabolism";
var content_f34_26_35247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Adenosine metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 546px; background-image: url(data:image/gif;base64,R0lGODlhKQIiAuYAAP/////MAICAgAAAAH9mAP8AAP/MM4iIiERERLu7u/+IiP9ERGZmZv+7uyIiIt3d3f/d3f8iIv9mZjMzM5mZmf+Zme7u7hEREf8zM/Dw8BAQEP8REczMzP/u7lVVVSAgIP/MzNDQ0KCgoDAwMLCwsMDAwP9VVYhtAEBAQODg4FBQUGBgYLuWAJCQkHd3d0Q2ACIbAP93d3BwcN2xAP+qqqqqqmZSAJl6ADMpAE8/Dz8zAH9mGZ9/ABEOAJ9/H++/L1VEAO+/AMyjAA8MAx8ZAI9yHO6+AA8MAM+lAC8mAE8/AM+lKaqIAK+MAHdfAB8ZBl9MAB8fH7+ZAK+MI49yAL+/v9+yAG9ZFt+yLF9MEw8PD8/Pzy8mCT8/P7+ZJu/v739/fz8zDK+vr29ZAG9vb9/f309PT19fX5+fnwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAApAiICAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6rCUC/v8AAwocSLCgwYMIEypcyLChwhL7IkpkJEAHgYsYM2rcyLGjx48gQ4ocSbKkyZA6BExcyXKQAAIBYsqcSbOmzZs4c+rcybOnz59AdxJQ2bJoxJdBkypdyrSp06BDjUrNh/Sp1atYs2aNOrUrvapaw4odS1YmV69o34Ety7at259n/9PKVbf2rd27d+PO3VuuLt6/gMPq5UsYnN/AiBMvHVy48bbDiiNL1snYsWVrkCdr3hyg8uXP0TJzHp3YM+jTzESTjvniRIABLGzCXm3VNOrbx1QnnTGg9wAYsmMzbf1aOM3ZtJ3axs1cmO6gvGfkRL6UOPWZ15MrXd68e6/nQKPLZDGASQAcNmz45n0Dhg0YvWEICXDCtxAW8AfcCGCdxY0BMaVXHG+94WAEeeTtF9MNPfR2Ank4/DZffvLRZx9+vSn4FnfedYgLeD8RGF8ATPQAxAsxITcAEDTB4IQQ1PWwX4n8uQbbfwHaUJxMvDFBnmszveDEeAPMBwSLMrkIo/9xMpLYQ15EeSjlLyD6JN5M6hmRonCzGaFebza0x6Nvvc3QH44BCAibEC/4dgN5NbEQ4Qv3AUgfDF76FiZwMYlYpl0cTinoK1X2dGVMTMDwAoqvmbfjf1qit6RMTcrUH3kzzIBecTbgEIAR+sF5ExA2iIoepOfZMGlMleIV6KCwqlIoT37CQJ4QRriXZpmzaRqfjvX1dh+FNe7YZg+bwsZCg/C9aWeQ8dVZYKYR/gbshcQCGmWs3Moyq3ZNiardq92WG8q34C4lbnLkmusuJ+imK+92275rbynxzquvT+3e6+8k+e4rcE79/muwIwEPrDBNBR/scCIJLyxxww9XTEj/xBIrTLHFFmOcscAbc/ywxx/rG7LIB1d00sost+zyyzCflBLKND/Sj0M456zzzjz3jDNENQct9NBEF2300UgnrfTSTDft9NNQRy311FRXbfXVWGet9dZcd+3112CHLfbYZJdt9tlop6322my37fbbcMct99x012333XjnrffefPft99+ABy744IQXbvjhiCeu+OKMN+7445BHLvnklFdu+eWYZ6755px37vnnoIcu+uikl2766ainrvrqrLfu+uuwxy777L0gcAA2ByBASAIDMMI77UXVMAADhtiOSe6s/P4I8oMor4jzwE+EAAIXWFCI8cVAzwjzgmh/iPfwDJBA//SHPDAABw5QIIgHvt1+QG8OcADAABP0pn4CFwxwgfou+MYB8gio3/AA8AABEo8QA6CAAxiQAAfYDwAN7M0BCtgb4h3AAfmbgAUcOAAHAAABvUGABXjHO/UJ4oIZHGHvKDgAFxBQgB74HfomaEAA5O59D/BG/0yIwPFdgnuqAOIPdWdDIi5CfIJAIs0OMIEi2tABObQdBy4gPxd4YH7u8+AFbkeB6g2gBoMAoO549wAPEO8BVETgFQGwPwDU4AJsvN36zkjFC1pggwdQnh0tMIE8DkCOYXTAHR3gRwB44IpTTIAHjMg79I3PjASsowN82A0LXGB6hlBiMYRoCU4ekf+SQeNgbx7AgAPajgJk8iASFWi+HM7vARccngUAeLtWijKBPSQgmQbQykHckgLMQwADeweAUp5wmIYIJjLTJwgEKJCHvLuACwHwS09mo4u9ZCES2Uc/FdYvje+jXxX9B8AasvCACFQgAzl4Pw7SsIIfNKD5KshCF96Ql4NggG/aKUHfMCB35pMf7zYIPw7oc5RIBOEARMi7b8rPXgNtpgv2SMgpPjSJ41NgHG1YvUHsj5a6LCM6C6HENnoUkJAMo+7QSIGIUrSQhUAeS393SABwQHyLbJ74tmjIkSLvpqDEBgJcaLyczi8BTLReH0n4QQbcVH4M0N0XVfrBMfISkmj/NCg8B7DGNr5xo3OMJAcQgMjzMa+mibxgUPPZRJ6ekIgAJF5KBeEAFypRfHtcakJHai4GrBEAXeSj/ghpQ38eFbAexJ/+KGDJ3mgQpK3Upisx2j0OJjZ/f5RsOLkKAMF6UKEMJSYhNnvF39Xzhb2JYe+myADN6s6a1Jgn/KhpQvEdtILKK6VGIejBWDJglrozni3JxEPKyhahk/0l9hLIPGZ+EJhGDCNmoYjPt1oXf620wG2Jd9cEGNOGyCwmX/cGW1hMYK3WYKIgLFkDtOJVgzoVRCmfasjofjS4tbzqeAdR0uK6taeEMJ7wYNlEQ5YVqdHVJRhdoEVAqteJ1HSA/+5QqVTugvGoL83tfvNWXr4QVr4eQB/9trlPDRdWnI3tJmR5KVmS+jCCHYQgZt85SoX+0ab5a60A7ZngD8LvshKc4vCYh8rxsXCBxUTo+ECrQvlumHzlwh6U8yZlzVV5Epo8hPjAxwneiQ+EPZ4yboIJSEpkOZMJ+F2HK9FHN3YUzWI+DZkvcWYXc3kTFxjfmiWy52SGuRN3dkQN4lcI+m7iyb3A7lRkG9UaGtKx1mNyQzsovxEn0HzjG+iWe1dOeD66m4jgJhwtq9VdArOgR500OFHNDeEtwgIxjumfF+HJK1si0I1wwIVHa2s3DrCzCoVvIja8Q0K4YNaZqPP2kP8dkWBalcBKPUBe/Si/mt74guLN9qadiEkyJhUAbU4mFA1R18P+NI1WTPVeLQqAdG9DobSeQJ5lPYlal/kSuF4EBQpMCO2W0nrXo571HiBCPCpiv5bEZBIXKgplv7q6RplzK287vO8eILzYXuVle7ntFZOSTPv9bme3a+4Jp1LdTkalbzzIDVwT0uK+GSM74wlPwrIXebelgMqZy2pBsNCMRBzqp/Pcu50Tr4sS/LSw5TtNQ+w3oM4dRLgRsV9sQpyT9ywjpId+4vhNOn63haVjK61OpN8Y3PdmyYOFy8tvn1CQeFTeBLibUZYHcI0dx29I3S6I/z7RlRQGN92dyG7//qaZmPNN4zcCPVD8WQCoTvQqHLvNS41qFIgMaKLx2O3u9Rkxsm0fNwRFC9gBWEDoJ4Tv1J9L9UOoF4gPHvYhhC5lrE/ShqqXtug5r9pqXxGJ9I3q/NaI+nymfSVCjmp+c8hNXEraNxPIocYFITwf5v2Dy/90AqcI8EEo9AJHHjzzNkt3E5O/G4GmuM5ZDtBdEnz5lkzABNSHvANMF/ulXzkhoo59FxBP5L+zb77xAPK3UKXmac1UXISwX7fkSpnXfa1XCMfFchDGa/IFciK3cx2kR6pUd5V1WBBUPwjwUP/UHPnWZ4kwUWnhPMI3COyVevSVUybVTNnHRHBUROaz/2Cf5UKFVwhGVVngJHq/U24DNghmxHcL2HSFMF4R9UEuUEA+9WYLmEwF9oIVSFW4130X5Eo9KHcWZlPnU18gaIQHtHqogWtotGsdYmPq04KC0EWDEFAHNQEyN1tsl0OwJkcA9GP5d2oIiFqcBW5G9H1qBj+8pFCE1nzFtW8RuIB/1UUa6EEecG/+9lv7B0h+NT8DaIHrs08+pj8nNjxeRj85dFBiJ04giIjyA2uThTckQAIR4XieEH+goGuHgGiJYEkQKAgMpoSnkG+NgIJtQwIakAH7MAG+qAkuwG+eMGgXlU+cYGipAIyLoGh8swIoEGd4kwEf0ALaeDcloAEh8P+NdiMAI0COdjMC9YKObxMCGgA07Bg3LfABxggNKRCPzIECKwAN/oCPuJEBGgCLzkACXeCPuEGM9cgMIRAFBokb2PgMA/AFDYka3OiNzYACYjCRqBGO45gaZKCRqGGOzVACDAmSp6GOzaABZWCSoOGO8JgMKwAGvDB3giCNoyCMkkCNs3d8sjOPCYkMJDkKwnNAvEOUA2Rj98aIb5V2/VNBuxgJ48ds+EZ6kdBrjIBEOjk5+sgMH1AFojA9HeVl1qNPxCNMo/eMtjhy/0YIb5RDHBB9nQRXUnlrVAkJVvlJpQOQApkMLVCQmyBquoQ+97NQB2BJNGmWbMRD5gOB4/X/RqDEOw50AdzkQqdVT4x2QQ60dB/EQQgQmQ+AaYgFWDP2c6blaPylTjCmPsZDarwDRjRJajm3Qjs2eg5lOQipDADplZmwhWHURMhTQi9nlmaJSpPVQEvoet90O0wlYaVnYDimSIiUZ+MHRZZUXJhUZNQ0QdNXfD9IU3T0jIEoefjnSy70Rj9IV3aVab2DVnnGVIhZOQ+pDALgl5ggctREJgTISw40VmXpic1DgfKlCFNUA8pjPENoQs7kXM4UlXRlncpJTLYDmhpVgCMYdUNIXLl0XIdYmCSXZNajXYaFlb2joC2FeLjIOBWJmx+QkccjhKYnUd4WXGX5dC8KjTFl/4mJVKAP6pxA5V5IVWDN5aCjR4Pzo5oAakbduZ4b1l8BdgCBR5ODdp0vSpNTRVMHZn5SGDkcqQwkEAUSiQnfl4lvSHSTJZwblpYBWggFmHQ6OqSVOZvJF6RNOqT4F04T8FkFRZqyuYmGV1l2SGML1EgbpGPw83/2s6ctRKfGNIm44XDtIJLKgAJncAtKmaZeoYuNUWwudjxz+QwomQwAiQa3QJOW6jkJ12OO2g4uqQwloAVbwJKTYHU5pE2PBGmqJj92Ok698T/BZU6m6Qw+qQwi4KqwWpVEdTtG9V7R5p5OFYbCN1XWRXkiJVbRsJXCSqy4YAHJ+Ak4GQlZOQvF1/8VE0hbGEVx4aVbLGecvgVc+Ddc/vkMerkMw8qitqCtocCgofCttNap8UWnjECLXvFg7OWjfKdhMWhf0NWu+mUNt8mlGkAGX0oL9goK+AoK+qoIOHmx/ocWH1ZMIZaZJGY/5jd2KfZYehdZAgRx0BCfypACKBAFujkLE0sIZudHkTmZgEiZO3aZDpCZENiZIeSZEupBTXk+egqIfLVZHKBYbRRA9ORPWQd91iNqllWavWFPPQtqblY5KcoMIvABXRCzhtACHWkKM+t9TbecJsejecaeCPZ2D1CdAWZy40NIQzs/u5akAJZVgwB5fcdF1SOt0wlKOcibdGqlz7mFcqv/S5azpcyQAV8bBWDwqiQ1ABqgAiJwj6Nwtt0jgksLoTtKoiSKr/xnoKB7t+tqoSOKoW9Igb30SneIr2O1TwBITAeagHLKuJYDqc5QAiugAVFgBmBQBV65SwPwAStAAj/JCZxLCGbUpojbowf2YLlLpG3qfAC6P3o7V4Tgtxtlf6e3fNRLRJnXWczlotYTvXhFRM71VZfzqdAQAiIgAyiAAsa7S+uICTVwAJ3XTAUFvYiqs1eLY0PGvkLapnYqSJilQUfbYmHkP0yrmssXp0SkWA6kmr1RPfUzSQEMYc61sZezqtZgvOr4kp1APWqYFgC7F69oFMFaDb2BvMpLCtjG/xfhOhcyMAAooLmUsAL5Ow7WSg2ZW6wucQU7MAACsLyMALkfgMTqEK9EjA0CsAMGgAVh0I1lmwiQqwIDkAM+sAM/PA4NG8XVIAI5YABoPAU5MASX2wImHAItwMVe/ANoDMbswLJkPA0ZMAB0jMZovARFkAVcMAAjsAIqoAFDMMd+XMdhPA5dm8fToAI+sMiUbABeUARFsASV7Md2DAB7eQ6OOwwnKgt3WTlmvMmojMpcIAIAkAIfsMPpwLuycHpbJ3uG8Jbww5PgZQjGOQlWWcqUs8d9nMrEvATFKAgZIABIrMTiAL+xQHCDpMvFZAhodEAH8FfJxIQAapc8CcyUI//JxBzOWbCPhBACKPABnzwOIlwLZnicMcWMulTLu6ym2/yGJjo/AqRztOuJxpN5p0holdMCZxzOqPwDQ5DFgyACGgDL5fDCsxB7jRhGG5aDGopEt3R29uxkWMRR48lW2Cd8vGc5ITAEBI3KPnCOiJABMqABjcwNQRwLD7gI41XDfcuGEs3L9dyc2qae73dC90c94Jd/s2U5GqDJJb3IBp3OhmDOH2DC3wDFrwCFCxhm44VGa3TN5QtrPHRxOP09LEal48NgTqhg7baDDABFPXg5KlAER73IOaACjqDQKsDD4DDGrRCJxZRglbiLa7pU+XPBN03PiABCF0Cl8JNR9oP/iJ91O2f9P4Zlm0MwzCU9BcfsCBnwuy2NDXi8C73YCql6Oiow0CWd1JJQAiPQ1OHwyLtgk6nw2aYDkGxd0m9dCS2gASvAzNkQypA8kh/wBJOcyj9QBJVNCZetARbpDbK8283wtU+QyZTsAzkwACrg1JNg2iNA3djgzMq93IecyDuwA0/wASKA27Rt2+RNDeu83c8Ax/7AyqCQAod83Nrg0OpdDyXwASOA0Nfw0sfQa958PL2BChdbOQKgATJw3tAA1adQsq0YYNUFQg1+PcfXa91lCbCGXp6gPLhW4aXQrY+Qb659L/CtAe6NDXadCsg42Ik6TxE+p8VzfCHeCDdl/woaXpebmgoe/jX3jQL6PQ2bveD8N7fVc2z4xGTap50euJoFFXYJFULepD/P+IkixEHohMtcFVi4Nz9U7lhPlEKypUFVO2KrRmlMXqugGEg+q3QWgEoanUCBmj/7c5m2k0CGhZndZOW/t+X0M6Q1i+eH9Xy1aTDKfODXoNqmoE+zJkzOtD+hd0d9xJsRup1lVm7dNW3MOlpwp1fvvH/qw0w3dtafiVdw17E5WONL5lTo9nvWh1Sih+lx+1G5x+ba1lWAy65PBEoUpriwjkCMDUWY9jvFB9Gi7uh+dOoO47Ikfg26fQrcG2AMgEqqRUrWXEqmhOShaTsgulWrbnHnOv9S3K49Wjd/RTRolMU869tMTsWGNZ5yJ9dd9omF6WOusm5MSPS6bSeXb5iysGTA4a4+SGTuhxeCBtjvR/Xt9/wwJPDKdC0NyS0KFLBGE3BFbojubHR4sDTquhfNRbqZ2PekX4hhGG9igRTNXIZthilH/05E585SWZ1AEWWwipdEFybqER6kBfvVg/e91TO+6Olr+96ggVRyGAU9c5VxrE7yB/8wybzM1aDdoWDlcDnxTaVTUeTkgnUBhJXA2Bd+ScZLTb5QTZZtDg722rNZJuQCb5byGEVaMtZBCeRZIwtPpvj1N2hd5KqIPlbYOR/BBPxPcGWIP09bZi/0KKeKg///9aGl0RzjsuiM3u/YEt6c47FDjAwdDfS9D8LzlH6mOP2YCyrN9NVKzvXtHJkNC0yN3aAakKNP+opAAj2+CnK98Mtw4qu/C52PCDJQ+qag0iy9stlY+75w+4cwAr8/C6fvDIYO/B8SxikQ4LZQ23M9kuJoDDH+CNVfldI8OMJfCCLQG0odC8Wt+1SC0qEAQsNmSnCZRC1+45vgqBXrCBS+6oCz/YSwAr0hA7lg3ag/DE4PCACCg4SFhoYMAwOHggwMAB4TFoQDD4yUCZeamgOZjAcIm5oIB4edoqipqqusra6vsLGys68CApcfiiO0vIwtGisZvcOuIRolxIIuEweL/4yODJKFlYfNihwDE4oUABSKA48HDg7ZFgnZAxccANYO66eDLt/YigygAAjkA/npDw+nFBzgK6XPXSJF/zIhUITAHDp1ySJKnEixosVDthiF+DYgxcVYGVZoaPHRYosPwoaJe+Dt0sEagw5+CzUImycAA0qJI+TNwkoLFyicU8iAA0QXHnDexAlT0D12oRCE8pbJwYGE3QSSIuTAhVJBncRZsMBsKL5HJdOqXctWYsZDLTiKaMuqxIgRyOj2QrGCmL5vzyZQgEjJUqGAmLJ204bwqQOhzhx5+yYQnlNyDHzSvLf1nCBSWBGTsiDzEbxOjpwy8Awgtd7XsGO/fmtIBf/HvrJFCQCWMnerDBpIRGzZmmbMcBcMg1Ve0zJAgV0B1KjkGHKjooTBLh0U9MAEp1FLsd46gFu+gT0BTDDdNKyDsVZZu/ZNv779WLQLaeD44T6jFCqM5F8qJGjQWy/EMWDcdZets1w18zzHjiLkPFCdfOF8Y9pNQCkiiVHgcCaeM1tZM4FWVzHmwCMHYbXQPg4xOOCMNNKYnyE31ihICR+gEIKOjKyAApBEFmnkkUgKkiMhSwK5mwwHEpnBByQlaeWVWGb5UZNK3mIlgBrMdWQJGvyo5Zlopqmmbl4ywiWRJPRoZpEC7LLmnXjmaeWbb0opwABQGjlCm3oWauihufH/SSiWKaDwgXBEGoNMBnkhaumlmLq1aCF9HhknCh4BeVKBKmRq6qmotqLomhn8KUCU/k35Taip1mqrrave2eijNIYwAkdV6kUCpLcWa+yWmzKZLJoiaADqgMZwZCddKQR37LXYRpRrnhnIMMCysvnK0ZxsoSBDtuimK8u2eobgaKX1ZYDCN+e2VSes6uarr5vgAtApsxqoQGt9KyjSH1sbkbvvwgx3qcm/aHarQb+viaAIsSVNGWzDHO/LLqK+fgCvbwXiltYKpXassr4fW/qLwPaFgFJazeK78s3FtmxpSALGa3NE1Y6M89C36nypXXihOkK9RDdddL8QF/pLMJnW/+n01bhCTfHOAW5sKJkKYy22pUafymPShgIn5thsk601trtRracKKbdtt6Flpwrm2mue9PPdgGuZd608+rimpIEnfufguGoQqF6KDDOo4pSnybitjYY5CAlhVxQ5LzIMWfnoWV5+66chAFdmWrnwDUuBA5Muu5Gm39rqAL8OsPpHFh8MkrWzB0/72w1b/M3MH+2HsSt8Ce88kbUXm/s3I/w9TMEmu+L389zbSPzCKUxPvfW8kKA7LAl3r75/0RebgQgijX/R579Ruf799bV/bQky/Fq9RfRjhZDwR8BEfQ9nKRCB1yISQFUUiHwFjGBF9Ce8BqKiWsuToAZLQsHgWf9QFObaoAjV0sHZffBh0xqhCid4wA2ekBFgW6EMKVJC2b3QEBqboQ611UIN3rAQdNuhEIdRQ9L9cBA1G6ISZ1HE0R0RAIhbohRr0UMJPnFyU8wiK5pYuSP2T4tgVAUXFde7TZApdmFMI46qeL9QtU4TalPj0WxBxzra8Y54zKMe98jHPvrxjihAwR4D+cdCGvKQiEykIu84smHJAn4AKGMJ9IiCiS3ykpjMpCY3yclOclJoFhGADghAylKa8pSoTKUqV8nKVrrylabUwShXKUtY2vKWuMylLltZS14uylvPYgUJBOCtW7xxBUpIZRKIUMpe7vKZ0IymNKdJzWpakwD/OthaMgRAgAB485vgDKc4x0nOcprznOhMJzhJaU52qvOd8IynPOfZzm6ekwd1U9IVdvAtCArCYvt8QgnMd7APIOGbSAhCAJAwgIN60530jKhEJ0rRilr0ohgNAAG0SQxuZvSjIA0nRMc50pCa9KQktac5gzCAAwlgBwbAQhio1DlCZCAuPjCAATpim1tkYADghMIReJAElWrUqChNqlKXytSPbnQtHm2qVNNZUpEidapYpWdVx6kEvokgBzo1wBRyMISA5dE2OZiCTrHQEUV4hAQ6+CZLFUEEhX5zq1nNq1736lSOEvGqfJUqXh8K2MAadp2FDScV8vnTH4RVp0so/8IOJkvZyfrAsWH1giAHkLKoBoAHHEmCQ4962NKa9rTlfCoJE4takA6WtK017WsRqgEg5vSxuM0tbnewglxACgVN+GYSODIAHtyVtbFNrnJRqtq0eHa5IX3tbKG71Ol68wjk+qput5vbHPTWdwOwqxU4coTRwpa66E0vRpvLQeSqd57Sde97oyvfAChhY43lrn4NMIQfmSkERPjmGL6RBLsed74ITvA72bul+ir4nPF9MFOtG4DF2na/211CbQnRAih8kwiKgIKBDyxhBbMAqCd4wUcHwIIJ+7UXzy2xPCMsY+bWFwkbRiJYMZzbIuQTAB8wbgCaoAgqkJPCNZ6qEP9woAgYnECcJw5Ailfc4uq+mBcxTrI6aaxl1zoYuzYdAGZ5HNYneDXA3lTCEaSQWgd3Wakz6IENvHkCIEAZxSrOKItdDFU3v5nLb16vg+97YTLr1Ae+E0SQvRkE0dYz0IY9AQ7ECQRF4MAIUZ7yN08MgwH0oNIDcEIAZsDkAcz5BJ0eAA5KzYQAqFoRNwjAC1IMgxt849Qw6PSlAwDqXaOTwRfJMqSPzFokD5uqDuZBCgFAgiGMmcdmJoQI0ByAIIw4pcfe6wnmDE5JGyEAODhBpvPszRO3GAYqtjWv5xxnIaB6BjMYwJNtoGJ5S7kHssbBDMBpayO82wg9uIG3wf3/5F9fmRbCzjZiH61wiiI5CGAmhAp2zOMiJBrIQt6ynxt+UVSH0wYcscG4wRllWT85yqmGtab3POU9n3gGs/bmDUo9gBloutYgvzVVD87EjWsZ0ByHr5uhkD0AAOe2+/XBADA27XgaO+gWjbOdpQyEgZcbzyQHqskDEGUgcJvOeWZ5vVvsBBhsPQAwEDUTan5zgft6yzxfl8+TDHSow9PYOI4SmXLwbNz+oAgD4NuUgnv3uds9oiwodbh5/Y0bjHzTWo95lEn9DZuHvcUtb3KLYy7lJrM9z7VmPKx33ufDL7zNpp+xn5OwwAyoYAhFWAJufZADzi5PlKpPve6jG3f8/xhexnXfPerhSWTXCYIEARpCDib7hA+IAFYpGIAVci/86lcU2KH8fYmDb32ryhO0xh9ECFpgi/ALAgU+f3r313/X3sMi4RznPvvPC0/ww2La19b4/PcP99LrXv7sp37eBFoLJAqut2ZapX38Z3rYN0EK+GAAuH4C6E1NQATO50AaoAT5t2APuIBQ14A01IEJFoHdN4HfxAMWKAAlgEaDcICEF1Em6IEM6H61IIIIRoLWF4MnCAU6oAh8cUcZuIHxNAY2KIPZBoITIUrXtIRMeErOlEpP2IRSOIVQWIRWIAWp9IISRWSzRIVe+IVgGIZNmE1rMUmedIZoaEeEREmClP+GbviGe/QBRYhSSrACcHiHeJiHeniHoAQ4Y1QoTUddLOVPcrREf1goiwZd+FSIjDgIh6gngbhcRGB+jahFj6gniZhcPHBxlZhGl5gnkRhbk9iJjPiJeZKJqEUFnEiKYGSKeEIC5dVaoJVBrGiJbJQuLVBXp2V/tShHrpgnK5AEpsWLvWgsC6AAvXCMevGLeTICHmZYxVeMerIABVCNBdAAmqAACwAAyniNDVAAjPCNoqCMdMGMeDIlRsZXSHAElCiNWrIAEsAK5AgA4ngI9agJ88gW5ognxpBxWdVoNOiONAKPg1AB1hiPEIAB1WgC2siNyHiNEVCNEQAB1ogBHRD/kQUQAQBgAtVokRtpjchYjreoL2Qyh/CkBD8mkGpCjdW4jYJgkB1gAi4JAA3ZjQ1wj4JAkTRQjwrgkRigAAowkQ65jCOpL76igVhFAP+jknhCkC+pkNUIARFQAYNQkw95k+AIACDAkgVQAfUoAdZYABIwloKQj1BVlPrieo7WVDywO0x5J04JABEQAwBAAwUAATJZldtok9/YAQAgARgAAB3QlX1Jkx4pCEHZARcZkvaClh4zVEsVBEpwDG+ZJ3GpABJ5lwm5kFYJANfYAQoZAQ2wARnZlaCZkR9ZjRVwmhsQAYypj465L3FCBP4IUk1wBCpAiJU5Q/toKSLwAbQJ/1KSCTy7qUa9eSm/SZtCOE88gJu6WZy8GZsdIwIjcARQYF7yZAUEcAQjQIvQaYsPE5DqEgIikQRUwGbwJAVQMAAr0IffCZ6XEDU38z4r8CtJAAU8sIFX2AQEkAQTw4LvuSZmWREDSpThOTol0AK2kUzYpANHoDuE1I4BupKvaREFKpIHKjvvYwsksIITaioGqZpdGQFjaY1UuQBQGY8VQJoFoADfGJogQJMdGaMjGpZUGRvH+aEBSo4FYAKFAJjcuI3fCAELQJeC8I0xagImAAIFEKMSsI09WpYVOhvSqaNW6go8io00yaIaqYwUCQENoJALAAI8OZUaSY8aeY1SKv8bufANOcYp4nmlcloIRSoIaqqTABADXYqMXzoIJiAB9YgBEsCkSQqlWlqnsVEw35CSDjOnjkoLIWqQhyqRewoAX8qSEUCmFQkBMloAGECjWhqpsGE8ilCA/hKnj5qqsICTQBJ931BT8qmqstoLrAokubOKjTqruqou3sKe8YmquxqsamI+gferwnqsh0ADmcqqaroJzboJ+diQr+FWxkoMz5oW14qswhMBNECPWTkI2XoI4XoI0TqTdIECywansBADXWkI48oK0qoKz1qr2po4FRCY3loI70oI+0oI5QobxJShrdABG7AA5mqnWqoW/VqviSMBRvqiGQmq3NiSfsn/kQWwAZ7ZAKDpoxbrkRbbooQQlKRpkU9alkZqESHgnbnKCivap5tZjdjYsR0AsRsQo5jpqTHKrtUIAjWZopbqs/yqsRhgAuIYlBHpkRiZqR3AkhjbABh5owzLMAtwo0i6kT56jYkJmkAplHZKAz9pmH75k0HJqdEaAYrpml/apzgad3WqjHmZsT0Zti6qpvBIqH8Jpd2KmHsppHf5p5Zas/zqtchYtBNJsFArlzFQmIKwAVRJAxgbtVJLtVkZlBlLljQ5lvEIrhuAr2B5kJb7r9wYj8cYA5m7tq5AkdaokVOJsJ1bjYCalWNZAWfqtDQZkRLQAZ35pRipmvy6uUcK/47SOpUd0LrxyK4boACoa42cCrn74rC/KwiCCrdmu5hjC673uo1xW5XT65ohu40QwLhoCriyEauIia8ESwNKqpVYe5j5+peD2qQbaa6Mm7t9W7r6er35GrwVAJMAEL2CwKTfe7jMuy/3+rsdyal0S7ETe7EZC5oW+bGrqZCt+Zo3G6XQe7CvkQIAugncKwgSsKRHq6YQ/JXxeLOfSrAdibt7yaeaCZV3GbQObJc06ZJT+bIk+o2ui6YSOcALw62yQbAJy8NC/BHKGqOwEQP4OsRKvMRM3MRO/Kj06gpRrAoX+sRWzAriWMWMEK/tCwtafMUTwa43GqIZGZJcOaVMOf/FWPytr/DFYJwMBGuwL3mmCnC8oeutRpzGuzuUnqqaFImNfXmMC+CaQrrHZFzCGIkBUNmto3mxJ4qMN5upThMwLVBTqSDGiNmuMkqVqRvEVkLJluwKLfvCsluVgemU4KsmoPwKmLy71aiNIIkmdpzFDwnJGEuWZIminNqQs8zGMDm2FImMJWvHK7q0CgACgBsDPto0/LECIrDBjBDHLomZ+BqRnEyVdawlzfzMs9C2yFjKz0uQBrm8abLN0FwI0jwI90iQVZslfUrLGeutYLoBfUqO2vjO4HivyiutanrPL+yZRKoAZIyaM7KHmERc1CMDKlsIo7zLESCaNECN16z/vuS8Rga9SAitCwr9CsmLmuBsmAusyalw0ZeU0biz0ZvQ0M9blpmbyllix5jJx9iop2U5tGs6wwAA0+A4l3V5l/yMjbxsy8aMzHm8pX7pCo6UhCSdSCYtSKHsr3SpjEGpAB9skBMtAWfKL0uNSE0tAE99CT0pCOcLznV8ovYrRlvN1Rnt1OMY1SG5zir6z1kSogrJxxKppXZ5qCHZkHQNvJkJAT+N040MvlJ9kBuJxqkATOe8CXZ4JdKC0qrQ0Ro5tgzcrqlb1Fby2AudCh38lyZAxqt7x3mi2ZEdlrP7rVwpwHeSrVy8FgR71K4gAPvUT6zwPrkArGzxAc682Fts/74bQAOUy5CeOdFootvcLDbGzduFENaC+dtdHJeGcq3fm7dI8lIxNVOVbIAigFY+sAO4bSSd/cGUa73DPcTh7aNwPUTapVNjVVYq0AIjM37cjVne/cb23Rb59ViRlQVcgDsoowHKd1m79d33fd9SSd21gXS65QVFEHvcVd8FzsStvapsTAijCduFsN6GlltcIKER/uGFMMUYoNqCkN8bHlYa9pwJ1Fsds+K4ikDw8+IbhKI53Lon6rOHLJfIeL5Oy7uCTMjcCLQyywgym7Sp+bjKfAkqoOAnngVFpwkk0D8cwTBRLj5XU+VTvkML4KN268GnzOXw+5IFgLuTrZHg6/+4Qb7LeyvP2fu1htDmc4uYXPuSGDwILUBxJ/4D/bUJISAA85LRaX1Iyp0Mff7nCB3ohjToalHoJo3ohaToh8KjFVDHOyzp+hyVQDziHX2X9rzClnqXrSuWhxDqr+vBZ10BdS4IITAEJx5WPpCuhoDlgO7ofgTpvSDrh07rfWTrH4HrxKXru34tymiXeErTw36XPE3sfxkBG+CXLj2UOO2lPs2+OU3B7FuY1TsISX4JGiB7eT4Em00ILp7l+jLugNE05v5EBXTGC/zQIQ3Jf/3pb23knT6UfQrByIzhqWmaobnAjzvimqACRdDqOcCoqCDfb7owCD82C6/liH3TJRH/Aw8vChcO5c624VNgICD+llrsxrlx4KIwcYam5+G+8SbPC8Ax8DxW8Cff8hbBI0/A5H5XBBrv8jYfEcAhAx/wBA7+WLTHWe5580L/CiEUScm3fDvQfM839EyPZUspfuQnAB7e9FQvCumjFws7jhOPCh5f9XKUQ2qxu1Ba0dTIwp5MrluPsGo/CF3v9Wk0QGsR2oIw59wYkRDwx1qPCu/a9m6vRQ8kC7yeyBXN9k+6AH9skKbeqU1a2BHbqZ/aunj/sciYtCCwtNXYtE/b90uEQbLw966wseT6upjZAIjvvkyasMdI1Hm6pPBbss2KtUKZj3OpuDnduI+r+UJU9LIQ/zqwMOF3bLGkD7sS8NEOOdBmeqRpqqXX+LkKMLyGbbzIG5ZyjfsydC+0APap0AALoJhuTqcICbNDmpDvi/rHLL7qW6iembewf7YCPeb9W7oA/OzUP0NXTwv1Lwovu/2h78EJDAgbGBIACgWHIAsKhYcFhIYFGCAAEocQBQ0dGAUbEQoQmwUREg2NhA0RhxEArK2ur7CxsrO0tba3uLm6u7y9vr/AwcLDxMXGwBkfLccCIxnH0NHS09TV1tfY2drbr6XcuCsq0Sgy3+bn6Onq6+ztx5sQ3QXDmMYiGs/QKRok7v7/AAMKHEgQVgNBi1x587evxDQS+ApKnEixosWLsv8kmKiwCgCqRgBAHXoUIRWGDgAWHFrQAUQoEwAwldq0YRKkCJNwjShHLRzGn0CDCh0arcMGGkYbANiwyJsJQhBqKogAwWiFqR00KVCAwZXMegskgKgJIAbMW82sJVtGtK3bt3CFVmjk6FI8b6kaXV3AKkIFCYQKSYBgIlKFmA0WAp7bqGOtEhpCDMuQT1aIyHEza97MGd2CGKxKGV1kCMBTVwr4AvCLtYOnVlMRKxZLFtdaYhlGpKCVtrPv38CD97qUc7UCxptChioAIXXfwyoLsIRU4PBXVoAZjbSlQlwxFRocztopvLz58+gF3qs8jMSAASJmNUxPv779+/rCQ9P/8H7FrPX4BSjggAS6Qh40K7w3AArsudJdgRBGKOFvvUETgoIDjCAZLLdN6OGHIM6ykD+Q7SbNBxhiBkuJIbbo4oQj+lKPMRloEN80LWCooSwVvujjj/XFyM6D1KSg4AcNvjKCAEA26eRvHx2i3HaVHAJdXgukskE8X9E0SZXVldUICFEe5koLSFoDngjK0DLfk3DG2RZTHs1zWlTFSdDVAnzNpdRrXykVlit6xkRDKxscRsMGrlwmXjUlPHPhhrKgmaScmGY6kF11rkbXVRuoklJT84wqW6nZKRCqKIWkIhZdzLWyJDfNXNoKkZrmqus/dJZ2GiuXHBrDKop0aup1/5QMVoCwji1VQaKwyDCCOeTQUuONu2arrTnIzSOSJdGVZOpCxSKbXbgRGHXISVF2xOI3+/Qzy7vb1muvcNeiA5GtrEh7778Ab4brOT7RMmvACCcMlKXqdGiZigpHLLFAl1GaTsW0MDzxxhynkxuT7fQYiwr+dWzyydjIgMI/B8pSo7woxywzMRCZ6M6bstQ888487/JyQADOonLPRBctCwolBzQwhwcb7XTPGgfkcCyTApDBo09nLXEIkg5gcUD0xoLmPd5pbXbCK9jYNEEiv5KMgjafLXe9GRzJL8sgwxLCCBiyNfff2Yqg49cC4dwof0cCrriufGOIbUFRN9r4e/+EL275j0YqCPFES7eSAQoKJn356D7KoKAzF+UrS4IDaED66y+iOMAKdw8U9iuCDwAz7LxH6N4Afv/k77walN378QOmvTtQa8OSAurIR39fbpVjhPEslMXCKSxhAjBXNkK2Er705NtWu0WR47L9K91/j8345cePH8m8rO+Vmd9/C1opWhZWAGj6m1IBnqKazzzrEFMRlf/YNY+pmAQlC0TJMYrXguq1hYIWlB/AfqaL7VWJELCyE0zGkph6RKBPIgQACU2gmpAwxy6fEV+puIISDCjAG1OpSqJoCAAbQgNDH1iBCOLWFiAKkYgaBJjOcmG/VrRvHn5hxQIqQC5Srcb/TFOMYisUEYNTbGIBZEIVXUjRQNX4BUyOaEUJBMDGNrrxjXB8I4Z0JIPlVSOOeMyjHgUwx9PVMYkIGxoTY8U9/KUQBMgqllNGiAkWKiQCtWHFU0RTiJPIsBBmvIolX7HGPXqSjX18DwoEkEFofPKUeAzlgkgJyIB9bJCNaGFMDCnA/ZVKkd4KBQBfwgoMFFAVINAEq/xXHRxm0jR6+aEf7UgUOjKzlfeq2kCSMpEgDpEz1kQiNBGWPn/EoCvbDGdoRLUL+AGlWuJMJ0HMWR4ObiwGppAgPKQYmEsopSLwHIk8CamSeKSEkOIkVyigoksVvgSHJYkESm5SnImQ4JkB/1tUPFxyF4TQE1gzmohEDVpRH/4TgJZQJ7n4UgrCjHADDeDKJXNolbFMwizq1MWi7tkKjXDkoi6kqURm+gqbdoRPG+hADPop0lsuwi5anCJhDGPM5zCGnDHFBVc4sQijIAWl/6SLTiUyVTpZlZphmWKiABrOKrrQpCrM6FSaekWXRvUXY6HBU9M4qJz+JK5zJURY5mKCkqazFKwqll0CSB0qlvE52knjW22hAAmghIQxrFMH6mrPijT2sSiNrGgGhVK/Lvaz3GjAcj5RgOJ4grIZlYhoG0Fa06YmMHXyJ2hnS9vaBiS1ts2tnOBpJq9stRfO0W1tr2kfo/CJe7+1SP8KRLCCD3Rmuc0VblBQgLX0PItT36pHBGfCCZus66Vjcs4CBipA2BaDBNLCkGbQO7kBSPec1UVPDIvlSMTw0IalENSrvsSXZcGGL8ct6Z0iCYwQCAB0oUSlgt8Y32kYGMF9XLCEG/zeYVDXPpdozBVZgQk0khE7EripR1aRQMeK96jMyYuV2pPeBEt4wRSOBntVuUcUjPLFbIxxhYFx4fqoFABWNQEjU7pJYwEGkZOoLyt2CGAUE8a8xoCu7N6TGSmrlzd52zE7ekyf12DHBCAwiXb1MhvtSEJdCj3xWbMr22OEoAXg6cyb44xlLbuDy3amCBvzvGUd8/kfe/5zOvD/LOiBBLrQ27gQhoyHaEBnudHYmDLwIB2QQ1P6Gqyj3KUdvWls5G4Azu00OyTtOlFPI3OzM/U6Mj0ARqvaGI173Ku/8elJzxoaphvA+W59agyVkte8cM+0gG2OxoWa2LgZAE+QvY1ci47ZwUABRKEtjd/Jmtq+eDS2rfEebW772wFBwbDBTW5DL7vc6PZHCKad7na7+93wjre85cbOeSP7iddYiJBwa29e49sa+i5Vv7+N79dYdbzbCeB4AbAoEDyVJA/MSwS4S5YudVc7OBn4pUPovVXcdAGMBIGQVYhVDJgAq62YSwdYmqiA6/dU+nUrTGdWrFvwm33JBcjNRY3v/6RgADoJqU5SD3MJ0HhvOc3JZMBBfCoQz7VZmsqnI/bpT9TqtOa22LkTc16NUgTG67GoeWqDWwuyv/ffXGGUqWjAnJEjUikmNyFo2J7051CyzOaiTUN1tVGKesSiKalnarFeC61zmOvUACxKKgFlKQYd8RunJZALkJDoUL6WKYGJqkBwE+YE1y/CnDiqQFhCplOn8XLiKaE28lPBX528Bj9KdktYiqt8FzEZVqhLDqF5YBKjFIowyiBGbKWnziUUh3HOQTgBHfKKl7zfQv1sDyJBwveuq1U9ClhhdXWSMuemN63vVxaBZEr0l6bB+jHJX3oWYdTeExLgrKIYJXbSkP+YL3R61mS9X/cAtx0qBFZbGGB0plI+eDVGgYdRV+dkPncYWoQsIoYKiJEIerFUP/d0v5dipRUWuQcuj9dxmLQ9zCFYntdkZ6Vi3aNxAHNZJNcAmlUAk+V6rkCC8ZB2kjRkC1F+jtRhXdEBKTgVbmUMJSVehAAtW2R09XBTztErQUWDamYXv6KCCbNaCEQcrXBaMrhFTjZ5CRFmkYAsZjYJMhEqqWB7K3Z6GShbg9Iu3mMlSXh/f8d8pmIXT/hCSMdrxAVN1CeF6EFoSTSAfNiHfhaIhFgLfliIiGgLh5iIjBgLi9iIkMgKjxiJjTiJlJiIlniJfKhoCuJqmliIkhb/PJ+IiKz2a6PYb592bKeIiKj2bKtIiLH2ioyYa7smi/ImbLaYiHVzbrkYiNLWi4iobcA4jMRYjMZ4jMiYjMq4jMzYjM74jNAoENYXjbQ1ItmBGrK0C4Q3jdQIWtYofcTAjd24WN84KlmifHmREH3he9SRCItATOo4jtMncOeCATWIf/EICxEQA2+nhTlUgPI4j61gAqBRc6nRREAGJiHWLIpwjeIYkOrkg+QHLQaJj7Cgcj30KjSlCK3hZRAJWgf0P47HCsq3Kur4LaOQWO4oTJ2Qjx/5kjAZkzI5kzRZkzZ5kziZkzq5kzzZkz75k0AZlIXWSThWlEZ5lEiZlErp/0aDKJTnIAA6QABSOZVUWZVWeZVYmZVauZVc2ZVe+ZVgGZZcqQPC6JTrIAAEEABquZZs2ZZu+ZZwGZdyOZd0WZd2eZd4mZd0SQBlaZbpgJZ6GZiCOZiEWZiGqZd86ZeAlpaH2ZiO+ZiQCZmJqZjuAJiReZmYmZmayZaTSZnsYJmbGZqiOZp52ZmeqQ6gSZqquZqsaZqniQ6pyZqyOZuY6ZqvaQ6xSZu6uZuEaZu3SSuMyZvCOZx46Zu/qQ25SZzKuZxraZzHiQ3JyZxveQIvEAAvcAJveZ3S+ZjO+ZzWEJ2GeQLvYQPZiZ2ESZ3WaZ5tqZ3b2Zjd6Z3UAJ7hWZ3lWf+Y6Mme66me7VmY7wmf0iCf9kmfA4AD73EDN6AgN3CdLwADNoCgAcACMPAeJzADBDoA5HmfEzoALBAANwAD6RkAEToAMCAEATAAHUqeaikEFQoEJVqhNxAADVqgDxqiE1qhKEqa/emfphSckYmeJYqdJ+Ch7PkCODADbGkDOBAAPaCeQECeM9ADQoChM6ChHCqk+gkDTlCiLMqWJ5CkazkAQNoDR5qkS7qWTRoAT0qiONqXOvqfPAqZPkqlHfqhdHoCPfAeMDClRqqWIVqgUiqnVmoEMWqhJbqhbDkDQDCgL0qlLDAAM2CneKqna9mnJqqaOdqmxQCg5ymgGzqnL5D/pR86pUwQAE7goWWqlme6lhhaoi+6oOl5oEYQADhAnlQ6nR5KpaUqqqRqqkx6o6t5qZg6DJoqmOJJqIDKoQU6pHjqoSxwp2BKoQryqNWpncWKA1YKrSJKq4aqqg6qIDCwoS+wrA/qrDUarZbKpsFqDMO6n5dZq+wKrOkKDOvKrpDprvsJr/GabW9Kr/y6pvl6R/varwKrmfj6r7swrwObsINZsAabCwirsBBbnOjasL/wsBF7sXPJsBRrCxaLsR7rlhq7sbwRsB9bsnUZsiLLIyRrsiwLlyibsrDQsS2LsS8Ls64AlWKZszq7szzbsz4rlmRps8RAlEtZtEZ7tEj7JWJNKbRM27RO+7RQG7VSO7VUW7VWe7VYm7Vau7Vc27Ve+7XxGggAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AMP: adenosine monophosphate; ADP: adenosine diphosphate; ATP: adenosine triphosphate; SAM: S-adenosyl methionine; SAH: S-adenosyl homocysteine.",
"    </div>",
"    <div class=\"reference\">",
"     With permission by Verani, MS, Mahmarian, JJ. Am J Cardiol 1991; 67:12D.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_26_35247=[""].join("\n");
var outline_f34_26_35247=null;
